[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 996
1. Irving JA, Alkushi A, Young RH, Clement PB: Cellular fibromas of the ovary: a study of 75 cases including 40 mitotically active tumors emphasizing their distinction from fibrosarcoma. Am J Surg Pathol; 2006 Aug;30(8):929-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular fibromas of the ovary: a study of 75 cases including 40 mitotically active tumors emphasizing their distinction from fibrosarcoma.
  • Cellular fibroblastic tumors of the ovary are currently classified as either cellular fibroma (CF) or fibrosarcoma.
  • The prognosis of cellular fibromatous tumors with > or = 4 MFs/10 HPFs and low-grade cytology is not established and it is the purpose of this study to investigate that aspect.
  • It has been our anecdotal experience that otherwise typical CFs with > or = 4 MFs/10 HPFs usually have a benign clinical course, suggesting that such tumors should be regarded as "mitotically active cellular fibroma" (MACF) rather than fibrosarcoma.
  • Seventy-five cellular fibromatous neoplasms were analyzed to determine their clinicopathologic features and the appropriateness of "MACF" as a designation for otherwise typical CFs with > or = 4 MFs/10 HPFs.
  • All tumors were unilateral.
  • The mean tumor size of CFs was 8.0 cm and 9.4 cm for MACFs.
  • The majority of the tumors were solid; approximately one-third of them had a cystic component.
  • Ovarian surface adhesions, involvement of the ovarian surface, or both, was present in 6% of CFs and 10% of MACFs.
  • All tumors consisted of cellular, intersecting bundles of spindle cells with bland nuclear features.
  • We conclude that cellular fibromatous neoplasms with bland cytology and elevated mitotic counts are associated with favorable patient outcome and should be diagnosed as MACF rather than fibrosarcoma, which usually have moderate to severe atypia and elevated mitotic rates.
  • [MeSH-major] Fibroma / pathology. Fibrosarcoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Mitotic Index. Prognosis

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861962.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. McKenney JK, Soslow RA, Longacre TA: Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol; 2008 May;32(5):645-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
  • Mucinous epithelial neoplasms arising in association with mature teratomas are a heterogeneous group of tumors, but with the exception of a single recent study, their full histologic spectrum, detailed immunophenotype, and association with classic pseudomyxoma peritonei (PMP) have not been fully studied.
  • The morphologic, immunohistochemical, and clinical features of 42 patients with mucinous epithelial tumors arising in association with mature ovarian teratomas were evaluated.
  • Tumor size ranged from 5.5 to greater than 200 cm.
  • Most teratoma-associated mucinous tumors were unilateral, although 1 patient harbored bilateral mucinous tumors in association with bilateral teratomas.
  • Using the 2003 World Health Organization criteria for ovarian intestinal type mucinous neoplasms, 17 (40%) were classified as mucinous cystadenoma, 16 (38%) as intestinal-type mucinous epithelial neoplasm of low malignant potential (IM-LMP), 4 (10%) as intraepithelial carcinoma (IEC), and 5 (12%) as invasive mucinous carcinoma.
  • Pathologic evaluation of the peritoneum in these 12 cases revealed 6 with acellular mucin alone, 3 with low-grade mucinous epithelium (all 3 with ovarian IM-LMP), and 3 with high-grade mucinous carcinomatosis (all 3 with ovarian mucinous adenocarcinoma).
  • The only adverse outcomes occurred in the 3 patients with ovarian carcinoma and associated peritoneal carcinomatosis.
  • We report that a significant proportion of mucinous tumors associated with mature ovarian teratomas present with clinical PMP, which in most cases is associated with IM-LMP.
  • Pseudomyxoma ovarii is common in this setting, particularly in tumors with IM-LMP histology, but pseudomyxoma ovarii is not predictive of PMP.
  • Ovarian teratoma-associated benign and IM-LMP mucinous neoplasms with microscopic peritoneal low-grade mucinous epithelium do not seem to be at significant risk for intra-abdominal recurrence, but numbers are few and follow-up is limited.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Mucins / metabolism. Neoplasms, Multiple Primary


3. Radin AI, Youssef IM, Quimbo RD, Perone RW, Guerrieri C, Abdel-Dayem HM: Technetium-99m diphosphonate imaging of psammocarcinoma of probable ovarian origin: case report and literature review. Clin Nucl Med; 2005 Jun;30(6):395-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Technetium-99m diphosphonate imaging of psammocarcinoma of probable ovarian origin: case report and literature review.
  • However, in several benign and malignant diseases, notably those characterized by extensive soft tissue calcification, Tc-99m MDP may be taken up by the tumor itself.
  • We present a case of a stage IIIC psammoma-rich low-grade serous carcinoma of the ovary, whose identity and extent of disease were first suggested by Tc-99m MDP scintigraphy.
  • [MeSH-major] Cystadenocarcinoma, Serous / radionuclide imaging. Cystadenocarcinoma, Serous / secondary. Ovarian Neoplasms / radionuclide imaging. Soft Tissue Neoplasms / radionuclide imaging. Soft Tissue Neoplasms / secondary. Technetium Tc 99m Medronate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891291.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  • [Number-of-references] 58
  •  go-up   go-down


Advertisement
4. Zhijun X, Shulan Z, Zhuo Z: Expression and significance of the protein and mRNA of metastasis suppressor gene ME491/CD63 and integrin alpha5 in ovarian cancer tissues. Eur J Gynaecol Oncol; 2007;28(3):179-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of the protein and mRNA of metastasis suppressor gene ME491/CD63 and integrin alpha5 in ovarian cancer tissues.
  • PURPOSE: To investigate the expression and significance of the proteins and mRNA of metastasis suppressor gene Me491/cd63 and integrin alpha5 in ovarian cancer tissues.
  • METHODS: RT-PCR and in situ hybridization were used to detect the expression of the proteins and mRNA of ME491/CD63 and integrin alpha5 in normal ovarian tissues (Group I), ovarian benign tumor tissues (Group II), ovarian borderline tumor tissues (Group III) and ovarian cancer tissues (Group IV), and the correlation between the expression and the age of patient, degree of differentiation, lymphatic metastasis, stage and pathological type was analyzed.
  • RESULTS: There was a significant change in gene expression between the well and moderately differentiated tumors and poorly differentiated tumors.
  • CONCLUSION: There is low expression of the proteins and mRNA of ME491/CD63 and integrin alpha5 in ovarian cancer.
  • [MeSH-major] Antigens, CD / metabolism. Integrin alpha5 / metabolism. Ovarian Neoplasms / genetics. Platelet Membrane Glycoproteins / metabolism. RNA, Messenger / analysis
  • [MeSH-minor] Antigens, CD63. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624082.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD63; 0 / CD63 protein, human; 0 / Integrin alpha5; 0 / Platelet Membrane Glycoproteins; 0 / RNA, Messenger
  •  go-up   go-down


5. Koensgen D, Freitag C, Klaman I, Dahl E, Mustea A, Chekerov R, Braicu I, Lichtenegger W, Sehouli J: Expression and localization of e-cadherin in epithelial ovarian cancer. Anticancer Res; 2010 Jul;30(7):2525-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and localization of e-cadherin in epithelial ovarian cancer.
  • BACKGROUND: Findings for the role of E-cadherin in ovarian cancer (OC) are controversial.
  • MATERIALS AND METHODS: Expression analysis of E-cadherin was performed by immunohistochemistry in 36 patients (12 primary OC, 15 recurrent OC, 9 benign ovarian lesions).
  • Tumor specimens were collected within OC.
  • RESULTS: E-Cadherin was significantly reduced in OC compared to benign ovarian lesions (p=0.024).
  • In primary OC, E-cadherin was comparable in ovarian tumor and corresponding metastatic tumor tissue.
  • [MeSH-major] Cadherins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis


6. Zheng Y, Katsaros D, Shan SJ, de la Longrais IR, Porpiglia M, Scorilas A, Kim NW, Wolfert RL, Simon I, Li L, Feng Z, Diamandis EP: A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res; 2007 Dec 1;13(23):6984-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy.
  • PURPOSE: Our goal was to examine a panel of 11 biochemical variables, measured in cytosolic extracts of ovarian tissues (normal, benign, and malignant) by quantitative ELISAs for their ability to diagnose, prognose, and predict response to chemotherapy of ovarian cancer patients.
  • EXPERIMENTAL DESIGN: Eleven proteins were measured (9 kallikreins, B7-H4, and CA125) in cytosolic extracts of 259 ovarian tumor tissues, 50 tissues from benign conditions, 35 normal tissues, and 44 tissues from nonovarian tumors that metastasized to the ovary.
  • CONCLUSIONS: The evidence shows that a group of kallikreins and multiparametric combinations with other biomarkers and clinical variables can significantly assist with ovarian cancer classification, prognosis, and response to platinum-based chemotherapy.
  • In particular, we developed a multiparametric strategy for predicting ovarian cancer response to chemotherapy, comprising several biomarkers and clinical features.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056174.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA120197
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


7. Turker O, Dogan I, Kumanlioglu K: Radioiodine accumulation in a large adnexal cystadenofibroma. Thyroid; 2010 May;20(5):561-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report a patient with marked radioiodine accumulation in a large adnexal cystadenofibroma, a benign ovarian tumor.
  • Pathologic examination revealed a benign cystadenofibroma without any coexisting thyroid tissue.
  • The mechanism for radioiodine accumulation in this patient's tumor is unclear.
  • [MeSH-major] Cystadenoma / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging
  • [MeSH-minor] Carcinoma, Papillary / radiotherapy. Carcinoma, Papillary / surgery. False Positive Reactions. Female. Goiter, Nodular / surgery. Humans. Hysterectomy. Iodine Radioisotopes / pharmacokinetics. Middle Aged. Ovariectomy. Thyroid Neoplasms / radiotherapy. Thyroid Neoplasms / surgery. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406107.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


8. Tyler KL, Bell MC, Ziebarth JA: A rare case of squamous cell carcinoma arising in a mature cystic teratoma of the ovary. S D Med; 2007 Oct;60(10):401-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of squamous cell carcinoma arising in a mature cystic teratoma of the ovary.
  • Mature cystic teratoma is a common benign adnexal tumor in females.
  • We describe a 43-year-old female with a 10 cm left ovarian mature cystic teratoma with the rare finding of squamous cell carcinoma.
  • [MeSH-major] Neoplasms, Squamous Cell / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fatal Outcome. Female. Humans. Hysterectomy. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019775.001).
  • [ISSN] 0038-3317
  • [Journal-full-title] South Dakota medicine : the journal of the South Dakota State Medical Association
  • [ISO-abbreviation] S D Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Stettner R, Bogusiewicz M, Rechberger T: [Matrix metalloproteinases and their inhibitors in ovarian cancer progression--diagnostic and therapeutic implications]. Ginekol Pol; 2009 Jan;80(1):47-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Matrix metalloproteinases and their inhibitors in ovarian cancer progression--diagnostic and therapeutic implications].
  • The research conducted in recent years has shown that metalloproteinases and their inhibitors contribute substantially to the ovarian cancer progression, participating both in in situ tumours growth, and the spreading of neoplasm via peritoneal fluid.
  • The assessment of serum concentration of some metalloproteinases and their inhibitors appeared to be useful in differential diagnosis between malignant, borderline and benign ovarian tumours.
  • Moreover, the pre-operational assessment of concentration of TIMP-1 in blood serum allows to select the cases of an ovarian cancer with an aggressive phenotype and unfavourable prognosis.
  • Despite great expectations, the usage of synthetic inhibitors of metalloproteinases did not bring significant changes and improvement to ovarian cancer treatment.
  • [MeSH-major] Biomarkers, Tumor / blood. Collagenases / blood. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / enzymology. Tissue Inhibitor of Metalloproteinases / blood

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19323060.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / Tissue Inhibitor of Metalloproteinases; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.- / Collagenases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  • [Number-of-references] 75
  •  go-up   go-down


10. Giordano G, D'Adda T, Gnetti L, Merisio C, Raboni S: Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature. Int J Gynecol Pathol; 2007 Jul;26(3):298-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature.
  • This neoplasm is very rare, with only 13 cases reported in the international literature.
  • In this paper, a new case of TCCE associated with benign ovarian Brenner tumor is described.
  • Moreover, immunohistochemical and molecular studies are carried out in the effort to establish the phenotype and etiology of this rare neoplasm.
  • The molecular study, by polymerase chain reaction (PCR) failing to reveal the presence of HPV DNA, demonstrates that neither the TCCE nor the ovarian Brenner tumor is caused by an HPV infection.
  • The association of TCCE with benign ovarian Brenner tumor could be a coincidental event.
  • Conversely, this finding could be the manifestation of a multicentric metaplastic process (neometaplasia), involving both the coelomic epithelium of the ovary and the Mullerian epithelium of the uterus, or the evidence of "field effect" that manifests differently at different anatomical sites.
  • In our view, other cases of TCCE associated with ovarian Brenner tumor should be reported to confirm the last 2 hypotheses.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Transitional Cell / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581415.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


11. Temkin S, Nacharaju VL, Hellman M, Lee YC, Abulafia O: Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer. Steroids; 2006 Nov;71(11-12):1019-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer.
  • In the ovary cortisol-cortisone inter-conversion is catalyzed by the enzyme 11beta-hydroxysteroid dehydrogenase (11beta-HSD).
  • Its role in carcinomas of human ovary is unknown.
  • The majority of ovarian cancers are derived from ovarian surface epithelium and the inflammation caused by successive ovulation seems to a play a role in the development of cancer.
  • Cortisol is known to act as anti-inflammatory agent and its metabolism by type 1 and type 11beta-HSD may control the inflammatory action by cortisol in ovary.
  • We undertook this study to investigate type 2 11beta-HSD activity which functions exclusively oxidative direction, in normal ovarian tissue compared to ovarian epithelial cancer.
  • Ovarian tissue was obtained from patients undergoing hysterectomy for both benign and malignant disease.
  • Mean type 2 enzyme activity was 0.87 +/- 1.65 pmol/min g tissue in normal ovarian tissue versus a mean enzyme activity of 2.96 +/- 1.37 pmol/mim g tissue in from cancer specimens.
  • Type 2 1beta-HSD activity in ovarian cancer specimens was significantly higher than enzyme activity measured in normal post-menopausal ovarian tissue.
  • Decreased cortisol levels due type 2 1beta-HSD activity may play a role neoplastic transformation as well as tumor proliferation in ovarian cancer by eliminating anti-inflammatory action of cortisol.
  • [MeSH-major] 11-beta-Hydroxysteroid Dehydrogenase Type 2 / metabolism. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Aged. Female. Humans. Isoenzymes / metabolism. Menopause. Middle Aged. Ovary / enzymology. Ovary / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17028049.001).
  • [ISSN] 0039-128X
  • [Journal-full-title] Steroids
  • [ISO-abbreviation] Steroids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 1.1.1.146 / 11-beta-Hydroxysteroid Dehydrogenase Type 2
  •  go-up   go-down


12. Yoshida A, Sarian LO, Andrade LA, Pignataro F, Pinto GA, Derchain SF: Cell proliferation activity unrelated to COX-2 expression in ovarian tumors. Int J Gynecol Cancer; 2007 May-Jun;17(3):607-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell proliferation activity unrelated to COX-2 expression in ovarian tumors.
  • The objective of this study was to assess the expression of Cyclooxygenase-2 (COX-2) and cell proliferation activity (Ki67 expression) in benign, borderline, and malignant serous and mucinous ovarian tumors.
  • Expression of COX-2 and Ki67 proteins were evaluated by immunohistochemistry, in paraffin-embedded sections of ovarian epithelial tumors.
  • The study included 113 serous (67 benign, 15 borderline, and 31 malignant) and 85 mucinous (48 benign, 28 borderline, and 9 malignant) tumors, removed from women who underwent laparotomy between January 1997 and December 2003.
  • From benign to malignant tumors, there was a progressive positive trend in COX-2 expression in both serous and mucinous tumors, more evident in mucinous ones (P < 0.001).
  • Comparing histologic types, COX-2 expression was more prominent in serous than in mucinous benign tumors (P < 0.01), but this difference was not significant in the borderline (P= 0.11) or malignant categories (P= 0.71).
  • There was a progressive Ki67 positivity in line with the tumor histologic gradient for both serous (P < 0.01) and mucinous lesions (P < 0.01), but this increasing expression did not correlate with COX-2 expression in the present series (P= 0.78).
  • There was a higher COX-2 expression in serous ovarian adenomas than in mucinous ones.
  • COX-2 positivity increases in line with the morphologic gradient, from benign to malignant in both histologic types, but it was more prominent in mucinous lesions, pointing to different oncogenic pathways related to different histologic types.
  • A correlation between the expression of COX-2 and Ki67 was not found, suggesting that COX-2 may be required for carcinogenesis, but this pathway is not responsible for cell proliferation in ovarian tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Cell Proliferation. Cyclooxygenase 2 / metabolism. Cystadenocarcinoma, Serous / metabolism. Membrane Proteins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Female. Humans. Ki-67 Antigen / metabolism. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504375.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


13. Gasim T, Al Dakhiel SA, Al Ghamdi AA, Al Ali M, Al Jama F, Rahman J, Al Suleiman SA, Rahman MS: Ovarian tumors associated with pregnancy: a 20-year experience in a teaching hospital. Arch Gynecol Obstet; 2010 Nov;282(5):529-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian tumors associated with pregnancy: a 20-year experience in a teaching hospital.
  • OBJECTIVE: Pregnancy associated with ovarian tumors was reviewed over a 20-year period to determine the maternal and fetal outcome in patients undergoing surgery during pregnancy.
  • METHOD: A retrospective study of 94 cases of ovarian tumors treated surgically during pregnancy was investigated for incidence, clinico-pathological features and outcome in a teaching hospital between June 1987 and May 2007.
  • RESULTS: The overall incidence of ovarian tumor in pregnant women was 1 in 505 (0.2%) deliveries.
  • Diagnosis of 69.2% tumors resulted in the first and second trimesters of pregnancy.
  • Twenty-two (23.4%) patients presented as an emergency at different periods of gestation and 16 (17.1%) tumors were incidentally discovered at cesarean section which underlines the significance of examining the ovaries routinely at cesarean section.
  • Benign teratoma (39.4%) and serous cystadenoma (24.5%) were the most common types of ovarian tumors found in the study.
  • The incidence of malignant tumors was 5.3%.
  • Tumors with low malignant potential comprised 40% of malignancy.
  • Whenever an ovarian tumor is detected in pregnancy, malignancy should always be suspected.
  • Treatment of an ovarian tumor in pregnancy should be tailored according to the age, parity, clinical presentation, gestational age and histopathology of the tumor.
  • Removal of persisting or enlarging ovarian masses as soon as possible is important to obtain a final histologic diagnosis and rule out malignancy.
  • Early diagnosis and appropriate treatment of malignant tumors offers the best prognosis for the patient.
  • [MeSH-major] Cystadenocarcinoma / pathology. Ovarian Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20049468.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Li S, Meng L, Zhu C, Wu L, Bai X, Wei J, Lu Y, Zhou J, Ma D: The universal overexpression of a cancer testis antigen hiwi is associated with cancer angiogenesis. Oncol Rep; 2010 Apr;23(4):1063-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The difference of mRNA expression in blood vessels derived from DLBCL and RLNH tissues was detected, and hiwi was overexpressed in tumor vessels of lymphoma.
  • Compared with that of chronic cervicitis (CC), hyperplasia of mammary glands (HMG), ovarian benign lesions (OBL) and endometrium benign lesions (EBL), the expression of hiwi, Ang-2 and Tie-2 was increased significantly in uterine cervical cancer (UCC), breast carcinoma (BC), ovarian cancer (OC) and endometrial cancer (EC) (P<0.01).
  • [MeSH-major] Neoplasms / blood supply. Neoplasms / metabolism. Neovascularization, Pathologic / metabolism. Proteins / metabolism
  • [MeSH-minor] Angiopoietin-2 / biosynthesis. Angiopoietin-2 / genetics. Argonaute Proteins. Biomarkers, Tumor / analysis. Cell Line, Tumor. Female. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis. Receptor, TIE-2 / biosynthesis. Receptor, TIE-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204292.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiopoietin-2; 0 / Argonaute Proteins; 0 / Biomarkers, Tumor; 0 / PIWIL1 protein, human; 0 / Proteins; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


15. Kline RC, Bazzett-Matabele LB: Adnexal masses and malignancies of importance to the colorectal surgeon. Clin Colon Rectal Surg; 2010 Jun;23(2):63-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article, the authors review both benign and malignant ovarian masses, as the colorectal surgeon who encounters an adnexal mass at the time of surgery should be aware of the steps necessary for surgical staging and optimal tumor resection.Ovarian tumors-most of which are benign-are divided into three major categories, in order of frequency: epithelial, germ cell, and sex cord-stromal tumors.
  • Nonneoplastic conditions of the ovary that may present as adnexal masses include the following, according to World Health Organization (WHO) classification: pregnancy luteoma, hyperplasia of ovarian stroma, hyperthecosis, massive edema, solitary follicle cysts and corpus luteal cysts, multiple follicle cysts, and endometriosis.Epithelial ovarian tumors arise from the surface epithelium and can be benign or malignant.
  • Germ cell tumors are more likely to appear in females under 20 years, accounting for 70% of ovarian tumors in this age group.
  • Teratomas are the most common germ cell tumors.
  • Malignancies, in addition to malignant teratomas, include dysgerminomas, endodermal sinus tumors, and embryonal carcinomas.
  • The more common sex cord-stromal tumors include granulosa stromal cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas.Surgical staging and optimal tumor resection are also addressed, with a focus on epithelial malignancies, as they are the most relevant to colorectal surgeons.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):77-81 [11277654.001]
  • [Cites] JAMA. 1983 Dec 9;250(22):3072-6 [6358558.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):30-5 [16021055.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):185-91 [16216320.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):383-90 [17005244.001]
  • [Cites] Obstet Gynecol. 2009 Apr;113(4):775-82 [19305319.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(4):343-51 [2246093.001]
  • [Cites] Curr Top Pathol. 1989;78:85-109 [2651026.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:15-25 [3665859.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):139-44 [2680797.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):921-6 [2685680.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):983-9 [3373267.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • (PMID = 21629623.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2967325
  • [Keywords] NOTNLM ; Adnexal masses / ovarian cancer / ovarian cysts
  •  go-up   go-down


16. Jeschke U, Bischof A, Speer R, Briese V, Richter DU, Bergemann C, Mylonas I, Shabani N, Friese K, Karsten U: Development of monoclonal and polyclonal antibodies and an ELISA for the determination of glycodelin in human serum, amniotic fluid and cystic fluid of benign and malignant ovarian tumors. Anticancer Res; 2005 May-Jun;25(3A):1581-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of monoclonal and polyclonal antibodies and an ELISA for the determination of glycodelin in human serum, amniotic fluid and cystic fluid of benign and malignant ovarian tumors.
  • We also found significantly increased glycodelin concentrations in the fluids of malignant ovarian cysts compared to benign ovarian tumors (p<0.001).
  • Its most promising application is expected in the diagnosis of ovarian cancer.
  • [MeSH-major] Antibodies / immunology. Glycoproteins / analysis. Ovarian Neoplasms / chemistry. Pregnancy Proteins / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033064.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies; 0 / Glycoproteins; 0 / PAEP protein, human; 0 / Pregnancy Proteins
  •  go-up   go-down


17. Shen Y, Li DD, Wang LL, Deng R, Zhu XF: Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer. Autophagy; 2008 Nov;4(8):1067-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer.
  • Our study was designed to investigate the expression and significance of two autophagy-related proteins, microtubule-associated protein 1 light chain 3 (LC3) and Beclin 1 in the tumorigenesis and development of epithelial ovarian carcinoma.
  • We observed that the positive expression of LC3 and Beclin 1 was significantly higher in the samples of benign and borderline ovarian tumors than those in malignant epithelial ovarian cancers.
  • Therefore, the decrease of autophagic capacity may be related to tumorigenesis and development of epithelial ovarian cancer.
  • [MeSH-major] Apoptosis Regulatory Proteins / biosynthesis. Autophagy. Carcinoma / metabolism. Cell Transformation, Neoplastic / metabolism. Membrane Proteins / biosynthesis. Microtubule-Associated Proteins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Cell Line, Tumor. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Neoplasm Staging


18. Koskas M, Martin B, Madelenat P: [Cystadenofibroma of the ovary: report of two cases]. J Gynecol Obstet Biol Reprod (Paris); 2009 Sep;38(5):431-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cystadenofibroma of the ovary: report of two cases].
  • [Transliterated title] Cystadénofibrome séreux de l'ovaire : à propos de deux cas.
  • Cystadenofibroma of the ovary is a relatively rare benign tumor.
  • Such tumors are characterised by their malignant macroscopical appearance which may lead to an inappropriate aggressive surgical approach.
  • We present two cases of cystadenofibromas of the ovary.
  • [MeSH-major] Adenofibroma / surgery. Cystadenoma / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19559542.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Zou L, He X, Zhang JW: The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer. Braz J Med Biol Res; 2010 Dec;43(12):1232-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.
  • Our objective was to estimate the efficacy of the measurement of serum YKL-40 alone or with CA125 as biomarkers for the diagnosis of epithelial ovarian cancer (EOC) using the YKL-40 ELISA kit.
  • An experimental group of 49 ovarian cancer patients included 42 patients with EOC (53 ± 15 years, range: 19-81 years) and 7 patients (48 ± 13 years, range: 29-36 years) with borderline epithelial ovarian tumor.
  • A control group of 88 non-malignant cases included 42 patients (43 ± 10 years, range: 26-77 years) with benign gynecological disease and 46 healthy women (45 ± 14 years, range: 30-68 years) at a teaching hospital.
  • Both YKL-40 (220.1 ± 94.1 vs 61.6 ± 48.4 and 50.1 ± 41.2 ng/mL) and CA125 (524.9 ± 972.5 vs 13.4 ± 7.6 and 28.5 ± 29.6 U/mL) levels were significantly higher (P < 0.05) in patients with ovarian cancer compared to the healthy and non-malignant groups.
  • YKL-40 had 92.9% sensitivity and 94.4% specificity for the diagnosis of EOC.
  • The correlations between serum YKL-40 and tumor stage, grade histology, performance status, patient age, and extension of debulking surgery were tested.
  • Serum YKL-40 alone or with serum CA125 levels are useful, although with some limitations, to diagnose ovarian cancer.
  • Our study showed that YKL-40 may not be an independent prognostic factor for ovarian cancer.
  • This prospective study may be a new trend in looking for biomarkers that optimize diagnosis of ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103788.001).
  • [ISSN] 1414-431X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Glycoproteins
  •  go-up   go-down


20. Lee YY, Kim TJ, Choi CH, Lee JW, Kim BG, Bae DS: Factors influencing the choice of laparoscopy or laparotomy in pregnant women with presumptive benign ovarian tumors. Int J Gynaecol Obstet; 2010 Jan;108(1):12-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing the choice of laparoscopy or laparotomy in pregnant women with presumptive benign ovarian tumors.
  • OBJECTIVE: To evaluate the factors associated with physicians' choice of laparotomy or laparoscopy in pregnant women with presumptive benign ovarian tumors.
  • METHODS: Retrospective comparative analysis of pregnant women who underwent laparotomy or laparoscopy for ovarian tumors and who delivered at Samsung Medical Center, Seoul, Korea, between July 1995 and April 2008.
  • RESULTS: Univariate analysis revealed that the following factors had a significant or a borderline significant association with the choice of operation type: maternal age (P=0.044); surgeon type (professor vs clinical fellow; P=0.094); tumor mass size (P=0.081); gestational age (P=0.035); and time since surgery (P<0.001).
  • Multivariate analysis showed that tumor size (P=0.030), gestational age (P=0.027), and time since surgery (P=0.004) were independent factors associated with physicians' choice of laparoscopy or laparotomy for the management of presumptive benign ovarian tumors during pregnancy.
  • CONCLUSIONS: In the latter years of the present study, physicians at the study center preferred the laparoscopic approach for managing presumptive benign ovarian tumors during pregnancy.
  • Furthermore, they preferred this approach to laparotomy for pregnancies at a relatively early gestational age and for treating small tumors.
  • [MeSH-major] Laparoscopy / methods. Laparotomy / methods. Ovarian Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19892330.001).
  • [ISSN] 1879-3479
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J: Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol; 2006 Sep;19(9):1149-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
  • Overexpression of IGFBP2 and IGFBP5 contributes to the invasiveness and progression of several human cancers, but their role and clinical significance in ovarian cancer has not been investigated in detail.
  • We examined IGFBP2 and IGFBP5 expression levels using two tissue microarrays, one containing six normal surface epithelium, six benign serous cysts, 10 serous borderline tumors, eight low-grade, and 20 high-grade serous carcinomas.
  • The other comprising 441 ovarian cancers of different histologic types linked to a clinicopathologic database.
  • Each tumor was sampled in duplicate with a 1.0-mm punch core needle.
  • IGFBP2 and IGFBP5 were overexpressed in high-grade serous carcinomas compared to normal surface epithelium, benign serous cysts, serous borderline tumors, or low-grade serous carcinoma.
  • They were differentially expressed in different types of ovarian carcinomas, being more often expressed at high levels in high-grade serous carcinoma, malignant mixed mullerian tumors and undifferentiated carcinoma, and more often expressed at low levels or not at all in clear cell and mucinous carcinomas.
  • We concluded that IGFBP2 and IGFBP5 might play a role in the development of high-grade ovarian serous carcinoma, but not in mucinous or clear cell ovarian carcinomas.
  • [MeSH-major] Carcinoma / metabolism. Insulin-Like Growth Factor Binding Protein 2 / metabolism. Insulin-Like Growth Factor Binding Protein 5 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. Image Processing, Computer-Assisted. Immunoenzyme Techniques. Neoplasm Staging. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 26 May 2006.
  • (PMID = 16729015.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 5
  •  go-up   go-down


22. Melo IA, Camargo Jde J, Gomes Bde M, Cabrera GA, Machuca TN: [Isolated mediastinal cystic lymphangioma]. Rev Port Pneumol; 2009 Jul-Aug;15(4):697-703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 59 years old female patient, asymptomatic, with the incidental finding of an ovarian tumor in her routine gynecological evaluation, and during the preoperative examinations it was incidentally found an isolated mediastinal tumor, and then routed to diagnostic evaluation of the lesion, which later proved to be a cystic lymphangioma.
  • The cystic hygroma of the mediastinum is a benign tumor and very infrequent, representing only 0.7 to 4.5% of all mediastinal tumors, and of these, only 1% is exclusively mediastinal in location.
  • The definitive diagnosis is only possible by pathological examination, and the recommended treatment consists of complete surgical resection.
  • Cases are described in isolated reports or series with few patients, and their readiness or synchronicity with other tumors, unknown, and to the best of out knowledge, not reported yet.
  • [MeSH-major] Lymphangioma, Cystic. Mediastinal Neoplasms

  • Genetic Alliance. consumer health - Lymphangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19547899.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


23. Vrzalova J, Prazakova M, Novotny Z, Topolcan O, Casova M, Holubec L Jr: Test of ovarian cancer multiplex xMAP technology panel. Anticancer Res; 2009 Feb;29(2):573-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Test of ovarian cancer multiplex xMAP technology panel.
  • BACKGROUND: An ovarian cancer marker panel including leptin, prolactin, osteopontin, insulin-like growth factor II (IGFII), macrophage migration inhibitory factor and CA125 was tested for multiplex marker measurement.
  • Multiplex was compared to single assayed tumour markers: CA125, TPS, thymidine kinase, monototal and HE4.
  • PATIENTS AND METHODS: The serum marker levels in ovarian cancer patients were compared to controls with benign ovarian disease. xMAP technology was used for multiplex panel and routine immunoanalytic methods for other markers.
  • Levels of all non-multiplexed tumour markers were significantly higher in the cancer group compare to the control.
  • The panel will be tested on a larger ovarian cancer cohort and in patients with other cancer and non-cancerous diseases.
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / blood

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331205.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / Peptides; 0 / beta-Defensins; 0 / tissue polypeptide specific antigen; EC 2.7.1.21 / Thymidine Kinase
  •  go-up   go-down


24. Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ: Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev; 2005 Feb;14(2):306-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
  • Epithelial ovarian cancer (EOC) is the leading cause of death among all gynecologic cancers in the United States.
  • Serum cancer antigen 125 (CA125) and a soluble isoform of the epidermal growth factor receptor (p110 sEGFR) have been studied individually as biomarkers of ovarian cancer.
  • In this study, we compare serum CA125 levels and sEGFR concentrations in women with EOC to women with benign gynecologic conditions of ovarian and non-ovarian origin.
  • We show that serum sEGFR concentrations are lower in patients with EOC than in women with benign gynecologic conditions, whereas serum CA125 levels are higher in patients to EOC compared with women with benign gynecologic conditions.
  • These data also reveal that age and serum sEGFR concentrations modify the association between CA125 levels and EOC versus benign gynecologic disease.
  • Hence, age- and sEGFR-dependent CA125 cutoff thresholds improve the ability of CA125 to discern EOC patients from women with benign ovarian tumors and non-ovarian gynecologic conditions.
  • Our analyses show that parallel testing with fixed sEGFR and CA125 cutoff thresholds optimizes sensitivity to detect EOC, whereas serial testing with age- and sEGFR-dependent CA125 cutoff thresholds optimizes test specificity, and overall accuracy to discern patients with EOC from women with benign ovarian and non-ovarian gynecologic conditions.
  • The combined use of serologic sEGFR and CA125, thus, has improved utility for screening and diagnosing EOC, which may increase the positive predictive value of a multimodal screening program that incorporates these biomarkers to detect and subsequently differentiate benign from malignant ovarian tumors.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Ovarian Neoplasms / diagnosis. Receptor, Epidermal Growth Factor / blood

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583
  • (PMID = 15734951.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / KO7 CA82520; United States / PHS HHS / / R01 57534; United States / NCI NIH HHS / CA / R03 CA82091; United States / NCI NIH HHS / CA / R21 CA82520; United States / NCI NIH HHS / CA / UO1 CA85133
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Protein Isoforms; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


25. Daponte A, Kostopoulou E, Kollia P, Papamichali R, Vanakara P, Hadjichristodoulou C, Nakou M, Samara S, Koukoulis G, Messinis IE: L1 (CAM) (CD171) in ovarian serous neoplasms. Eur J Gynaecol Oncol; 2008;29(1):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L1 (CAM) (CD171) in ovarian serous neoplasms.
  • PURPOSE OF THE INVESTIGATION: The evaluation of L1 (CAM) as a tumor progression marker and as a prognostic factor in serous ovarian tumors.
  • METHODS: L1 (CAM) protein expression was assessed by immunohistochemistry and Western blot in serous ovarian tumors [cystadenomas (n = 20), borderline tumors (n = 14) and carcinomas (n = 47)], and was correlated with stage,grade, progression-free survival time (PFS) and overall survival.
  • It increased from benign tumors to early carcinomas and to advanced stage carcinomas progressively and significantly.
  • In Stage III G3 carcinoma patients, low L1 (CAM) expressing tumors exhibited better response to chemotherapy and were associated with statistically significantly longer PFS (p = 0.002).
  • CONCLUSION: L1 (CAM) expression represents a novel diagnostic marker in serous ovarian neoplasms that shows characteristics of tumor progression.
  • [MeSH-major] Biomarkers, Tumor. Disease-Free Survival. Neoplasms, Cystic, Mucinous, and Serous / metabolism. Neural Cell Adhesion Molecule L1 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386459.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecule L1
  •  go-up   go-down


26. Su WH, Cheng MH, Tsou TS, Cheung SM, Chang SP, Wang PH: Port wound closure assisted by Foley catheter: an easier way to provide fascia security. J Obstet Gynaecol Res; 2009 Aug;35(4):725-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Ninety-six patients with benign ovarian tumor warranting laparoscopic surgery were enrolled into the study.
  • [MeSH-minor] Adult. Female. Humans. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19751334.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


27. Skalicky T, Treska V, Liska V, Sutnar A, Molacek J, Mirka H, Ferda J, Ohlidalova K: The rare benign liver tumors. Bratisl Lek Listy; 2007;108(4-5):229-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The rare benign liver tumors.
  • As opposed to malignant secondary tumors, metastases of the colorectal carcinoma are benign tumors of the liver that are quite rare in the Czech Republic.
  • From the 55 patients operated on since 2000 at our department for benign liver tumors, the most frequent are haemangiomas, focal nodular hyperplasia (FNH) and hepatocelular adenoma.
  • Only 7.3% of them form a different histological type of a tumor than this most frequently occurring trio of tumors.
  • The authors describe three cases of rather rare liver tumors with benign behavior that have the potential of becoming malignant.
  • It concerns mucin producing biliary tumors, which correspond to the pancreatic intraductal papillary mucin tumor, hepatic cystadenoma with ovarian stroma and a liver hamartoma in an adult patient (Ref 13).
  • [MeSH-major] Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Cholangitis, Sclerosing / diagnosis. Cholangitis, Sclerosing / surgery. Cystadenoma / diagnosis. Cystadenoma / surgery. Female. Hemangioma, Cavernous / diagnosis. Hemangioma, Cavernous / surgery. Humans. Middle Aged. Pancreatic Ducts. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694811.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  •  go-up   go-down


28. Levens ED, Whitcomb BW, Csokmay JM, Nieman LK: Selective venous sampling for androgen-producing ovarian pathology. Clin Endocrinol (Oxf); 2009 Apr;70(4):606-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective venous sampling for androgen-producing ovarian pathology.
  • PATIENTS: Four hyperandrogenaemic women and an additional 132 previously reported cases with available testing data and a pathological diagnosis were evaluated.
  • MEASUREMENTS: Serum androgens, diagnostic imaging and ovarian venous effluent sampling.
  • Criteria to distinguish ovarian tumours from other ovarian conditions and to localize the lesion(s) were evaluated.
  • RESULTS: Basal peripheral testosterone levels >or= 4.51 nmol/l (>or= 130 ng/dl) discriminated ovarian tumours from benign causes of hyperandrogenism (sensitivity: 93.8%, 95% CI 85.0-98.2; specificity: 77.8%, 95% CI 66.4-86.7).
  • In women with peripheral testosterone >or= 4.51 nmol/l, a right-to-left (R:L) ovarian testosterone ratio >or= 1.44 correctly identified all 18 women with right-sided tumours and misclassified two with bilateral lesions; 12 out of 14 women with left-sided or bilateral lesions had a lower R:L value.
  • When this criterion was combined with a left-to-right (L:R) ovarian testosterone effluent ratio of > 15 to identify left-sided tumours, overall 66% of women were correctly categorized.
  • CONCLUSIONS: Peripheral testosterone concentrations identified ovarian androgen-producing tumours, and venous sampling could correctly localize 66% of these, suggesting a role for sampling when imaging studies are not revealing.
  • [MeSH-major] Androgens / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis. Testosterone / blood
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Child. Diagnosis, Differential. Female. Humans. Hyperandrogenism / blood. Hyperandrogenism / diagnosis. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):254-7 [14529690.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Jul;59(1):34-43 [12807501.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):453-62 [14764747.001]
  • [Cites] AJR Am J Roentgenol. 2004 Nov;183(5):1411-5 [15505313.001]
  • [Cites] J Clin Endocrinol Metab. 1971 Aug;33(2):199-209 [4935635.001]
  • [Cites] Am J Obstet Gynecol. 1974 Sep;120(1):91-6 [4276926.001]
  • [Cites] Fertil Steril. 1975 Sep;26(9):877-88 [126875.001]
  • [Cites] Am J Obstet Gynecol. 1976 AUG 1;125(7):1000-7 [941940.001]
  • [Cites] Am J Obstet Gynecol. 1977 Sep 1;129(1):108-10 [900162.001]
  • [Cites] Obstet Gynecol. 1977 Nov;50(5):623-7 [909673.001]
  • [Cites] Obstet Gynecol. 1978 Jul;52(1):73-8 [150557.001]
  • [Cites] Obstet Gynecol. 1978 Nov;52(5):609-12 [214729.001]
  • [Cites] Obstet Gynecol. 1979 Jan;53(1):36-43 [215947.001]
  • [Cites] Am J Obstet Gynecol. 1979 Feb 15;133(4):457-8 [219693.001]
  • [Cites] J Clin Endocrinol Metab. 1979 Sep;49(3):381-6 [224075.001]
  • [Cites] Int J Gynaecol Obstet. 1978 Jul-1979 Aug;17(1):78-82 [39844.001]
  • [Cites] Obstet Gynecol. 1980 Jul;56(1):99-102 [6247678.001]
  • [Cites] Obstet Gynecol. 1981 Apr;57(4):525-31 [7243109.001]
  • [Cites] Int J Gynaecol Obstet. 1981 Dec;19(6):467-72 [6121729.001]
  • [Cites] Fertil Steril. 1984 Oct;42(4):585-93 [6237938.001]
  • [Cites] Cardiovasc Intervent Radiol. 1986;9(2):75-82 [2942254.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Nov;63(5):1204-10 [3760120.001]
  • [Cites] Fertil Steril. 1986 Dec;46(6):1005-10 [3781020.001]
  • [Cites] Am J Obstet Gynecol. 1988 Jun;158(6 Pt 1):1313-22 [3289393.001]
  • [Cites] Gynecol Endocrinol. 1988 Dec;2(4):331-8 [3232554.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Jul;71(1):1-4 [2196276.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Nov;33(5):613-8 [2253412.001]
  • [Cites] J Reprod Med. 1991 Jul;36(7):546-8 [1941793.001]
  • [Cites] J Endocrinol Invest. 1991 Dec;14(11):949-56 [1806613.001]
  • [Cites] Acta Obstet Gynecol Scand. 1992 Apr;71(3):245-8 [1317653.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 Oct;39(4):491-5 [8287578.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1214-8 [8630900.001]
  • [Cites] Mt Sinai J Med. 1997 Mar;64(2):130-5 [9057471.001]
  • [Cites] Acta Paediatr. 1998 Nov;87(11):1138-45 [9846915.001]
  • [Cites] Ann Acad Med Singapore. 1998 Sep;27(5):712-6 [9919347.001]
  • [Cites] Fertil Steril. 2005 Jul;84(1):218 [16009186.001]
  • [Cites] Gynecol Endocrinol. 2005 Oct;21(4):238-41 [16316848.001]
  • [Cites] Gynecol Endocrinol. 2005 Sep;21(3):138-41 [16335905.001]
  • [Cites] Curr Opin Urol. 2007 Jan;17(1):32-8 [17143109.001]
  • [Cites] Med Klin (Munich). 2007 Mar 15;102(3):259-62 [17345023.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Aug;92(8):3040-3 [17519304.001]
  • [Cites] Med Sci Monit. 2008 Feb;14(2):CS9-12 [18227769.001]
  • [Cites] J Obstet Gynaecol Res. 1999 Aug;25(4):231-6 [10540524.001]
  • [Cites] Hum Reprod. 2002 Jun;17(6):1468-71 [12042263.001]
  • [Cites] Gynecol Endocrinol. 2002 Jun;16(3):213-6 [12192893.001]
  • [Cites] Australas J Dermatol. 2003 Feb;44(1):62-6 [12581085.001]
  • [Cites] Fertil Steril. 2003 Dec;80(6):1504-7 [14667891.001]
  • (PMID = 18721192.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 HD008832-01
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens; 0 / Biomarkers, Tumor; 3XMK78S47O / Testosterone
  • [Number-of-references] 47
  • [Other-IDs] NLM/ NIHMS74742; NLM/ PMC2656419
  •  go-up   go-down


29. Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS: Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int; 2008 Dec;58(12):749-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer.
  • AKT plays an important role in malignant behavior of tumors.
  • The purpose of the present study was to determine the expression of phosphorylated AKT (P-AKT) and nuclear factor-kappaB (NF-kappaB) p65 and their association with clinicopathological parameters and prognosis in epithelial ovarian tumor.
  • On immunohistochemistry 115 samples of ovarian tissue that included 68 specimens of epithelial ovarian cancer, 12 of borderline tumor, 24 of epithelial benign tumor and 11 of normal ovary, were evaluated.
  • Sixty-three patients with ovarian cancer were followed up from 7 to 68 months.
  • The positive expression rate of P-AKT and NF-kappaB p65 were higher in epithelial ovarian cancer than in normal ovarian tissue (P<0.01).
  • Elevated expression of P-AKT was negatively correlated with the survival of ovarian cancer patients, but it was not an independent prognostic factor after multivariate analysis.
  • Overexpression of P-AKT and NF-kappaB p65 were involved in the carcinogenesis and metastasis of ovarian cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Transcription Factor RelA / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Phosphorylation. Prognosis. Survival Rate. Up-Regulation. Young Adult


30. Shan SJ, Scorilas A, Katsaros D, Rigault de la Longrais I, Massobrio M, Diamandis EP: Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. Clin Chem; 2006 Oct;52(10):1879-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols.
  • Reports indicate that in ovarian cancer, KLK7 is significantly up-regulated at the mRNA level.
  • The aim of this study was to determine whether hK7, measured quantitatively by ELISA in ovarian cancer cytosols, is a prognostic biomarker for ovarian cancer.
  • METHODS: We used a newly developed ELISA with 2 monoclonal antibodies to quantify hK7 production in 260 ovarian tumor cytosols and correlated these data with various clinicopathologic variables and patient outcomes [progression-free survival (PFS) and overall survival (OS)] over a median follow-up period of 52 months.
  • RESULTS: Median (range) hK7 concentration in ovarian tumor cytosols was 2.84 (0-32.8) ng/mg of total protein.
  • Compared with healthy and benign ovarian tissues and nonovarian tumors that metastasized to the ovary, malignant ovarian tumor cytosols highly overproduced hK7 (P <0.001).
  • We used the median value as the cutoff value to categorize tumors as hK7-positive and hK7-negative.
  • Women with hK7-positive tumors most frequently had advanced-stage disease, higher tumor grade (G3), suboptimal debulking, and serous or undifferentiated histotype (P <0.001).
  • Kaplan-Meier survival curves confirmed an increased risk of relapse in women with hK7-positive tumors (P = 0.009).
  • CONCLUSIONS: hK7 is associated with other unfavorable characteristics of ovarian cancer, but it is not an independent prognosticator for ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cytosol / chemistry. Kallikreins / analysis. Ovarian Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916986.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK7 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


31. Song T, Choi CH, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG: Pediatric borderline ovarian tumors: a retrospective analysis. J Pediatr Surg; 2010 Oct;45(10):1955-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric borderline ovarian tumors: a retrospective analysis.
  • BACKGROUND/PURPOSE: Borderline ovarian tumors (BOTs) are uncommon in the pediatric population, and there have been limited studies that have included a small number of patients.
  • RESULTS: Twenty-nine patients (median age, 18 years) had a large-sized tumor (median, 19.8 cm).
  • The permanent section histology revealed 25 mucinous (86.2%) and 4 serous type tumors (13.8%).
  • In 2 cases, the suspected recurrences were found to be other benign ovarian tumors.
  • In one case that was initially treated with left ovarian cystectomy for a mucinous BOT, subsequent left salpingo-oophorectomy confirmed recurrence of a mucinous BOT at 16-month follow-up.
  • The last case was a newly developed primary ovarian mucinous carcinoma with no evidence of recurrence of a previous mucinous BOT at 26-month follow-up.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / pathology. Cystadenoma, Serous / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Female. Humans. Infertility, Female / prevention & control. Ovariectomy / adverse effects. Ovariectomy / methods. Ovary / pathology. Ovary / surgery. Retrospective Studies. Salpingectomy / methods. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20920712.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Zhang WY, Pan Y, Zhu LR, Zhang JZ, Zhang M, Feng K, Zhou L, Yu L, Zhang XM, Ng SW: [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor]. Zhonghua Yi Xue Za Zhi; 2005 Nov 9;85(42):2988-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].
  • OBJECTIVE: To investigate the expression status of topoisomerase IIIa in epithelial ovarian tumor and the relationship between the expression status of topoisomerase IIIa and pathological type and clinical stage of epithelial ovarian carcinoma.
  • METHODS: Immunohistochemistry was carried out in the samples of ovarian tumor obtained during operation from 169 patients, aged 28 approximately 59, 18 cases with serous cystadenoma, 30 cases with serous borderline cystadenoma, 37 serous cystadenocarcinoma, 10 cases with mucous cystadenoma, 20 mucous borderline cystadenoma, 26 mucous cystadenocarcinoma, 19 cases with endometrial carcinoma of ovary, and 9 cases with clear cell carcinoma.
  • RESULTS: The expression rate of topoisomerase IIIa was 17.9% in the benign ovarian tumors, 74.0% in the borderline cystadenoma, and 42.7% in the malignant tumors with statistical significance among them (chi(2) = 24.657, P < 0.001).
  • There was no correlation between the expression of topoisomerase IIIa and the clinical stage or pathological grade of the tumors (P = 0.903 and P = 0.844).
  • CONCLUSION: Topoisomerase IIIa is highly expressed in epithelial ovarian carcinoma, and its expression level is correlated with the character and type of tumor tissues.
  • [MeSH-major] DNA Topoisomerases, Type I / biosynthesis. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Adult. Cystadenoma, Mucinous / enzymology. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / enzymology. Cystadenoma, Serous / pathology. Female. Humans. Immunohistochemistry. Isoenzymes / biosynthesis. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324386.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Isoenzymes; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.2 / DNA topoisomerase III
  •  go-up   go-down


33. Stewart CJ, Brennan BA, Koay E, Naran A, Ruba S: Value of cytology in the intraoperative assessment of ovarian tumors: a review of 402 cases and comparison with frozen section diagnosis. Cancer Cytopathol; 2010 Jun 25;118(3):127-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of cytology in the intraoperative assessment of ovarian tumors: a review of 402 cases and comparison with frozen section diagnosis.
  • BACKGROUND: Intraoperative pathological assessment is frequently requested in patients with suspected ovarian neoplasia so that optimal surgical management can be performed.
  • In this study the accuracy of intraoperative cytology has been assessed and the results compared with frozen section diagnosis.
  • METHODS: The study comprised 402 ovarian tumors that were submitted for intraoperative assessment in which both cytology preparations, usually scrape smears, and conventional frozen sections were examined.
  • Each technique was evaluated independently, although the diagnosis transmitted to the surgeon was based upon the combination of the clinical, macroscopic, histological, and cytological information.
  • The results were compared with the final pathological diagnosis in each case and cases with discordant diagnoses were reviewed.
  • RESULTS: There were 226 benign lesions, 35 borderline epithelial neoplasms, and 141 malignant tumors according to the final pathological diagnosis.
  • All benign lesions were accurately categorized using both frozen section and cytology.
  • Thirty (86%) of the borderline tumors and 137 (97%) of the malignant tumors were accurately identified on frozen section, whereas the corresponding results for cytology were 23 (66%) and 131 (93%), respectively.
  • Cytological evaluation provided better morphologic detail, permitted wider tumor sampling, and directed appropriate ancillary investigations in some cases.
  • However, cytology has a complementary role in the intraoperative assessment of ovarian neoplasia and provides a more specific diagnosis in some cases.
  • [MeSH-major] Cytodiagnosis. Frozen Sections. Intraoperative Period. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Cancer Society.
  • (PMID = 20544702.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Cho H, Kim JH: Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J Histochem Cytochem; 2009 May;57(5):513-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer.
  • We recently identified lipocalin2 (LCN2) as being upregulated in ovarian cancer cell lines.
  • The purpose of this study was to validate LCN2 upregulation in ovarian cancers and to investigate its potential as a serum biomarker.
  • We assayed LCN2 expression in ovarian cancers using real-time PCR and IHC.
  • To evaluate the potential of LCN2 as a biomarker, we measured serum LCN2 levels in 54 ovarian cancers, 15 borderline and 53 benign ovarian tumors, and 90 healthy controls.
  • SYBR green PCR and IHC showed LCN2 overexpression in ovarian cancers.
  • LCN2 immunoreactivity was significantly associated with tumor differentiation (p=0.009), as well-differentiated tumors showed the highest LCN2 expression.
  • Serum LCN2 level in ovarian cancer was significantly higher than in the other study groups (p<0.001), and in accordance with IHC results, it also correlated with tumor differentiation, with well-differentiated tumors having the highest value.
  • The sensitivity and specificity of LCN2 in detecting ovarian cancer was 72.2% and 50.4%, respectively.
  • In conclusion, LCN2 expressions are upregulated and related to tumor differentiation in ovarian cancers and should be included in future research assessing potential biomarkers for ovarian cancer.
  • [MeSH-major] Acute-Phase Proteins / biosynthesis. Biomarkers, Tumor / biosynthesis. Lipocalins / biosynthesis. Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins / biosynthesis
  • [MeSH-minor] Adult. Cell Line, Tumor. Female. Fluorescent Dyes. Humans. Immunohistochemistry. Middle Aged. Neoplasm Recurrence, Local. Polymerase Chain Reaction. Prognosis. Proportional Hazards Models. ROC Curve. Reference Values. Serum. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1997 Jun;28(6):734-9 [9191009.001]
  • [Cites] Biochem Soc Trans. 1997 Feb;25(1):75-80 [9056847.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1483-7 [9626466.001]
  • [Cites] Int J Cancer. 1998 Dec 18;79(6):565-72 [9842963.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 16;97(4):251-3 [15713956.001]
  • [Cites] Mol Cell Biochem. 2005 Jul;275(1-2):25-55 [16335783.001]
  • [Cites] Adv Cancer Res. 2007;96:1-22 [17161674.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2426-34 [17294443.001]
  • [Cites] Breast Cancer Res Treat. 2008 Apr;108(3):389-97 [17554627.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1540-7 [18392050.001]
  • [Cites] Mol Cell Biochem. 2008 Dec;319(1-2):189-201 [18682896.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jan;58(1):15-23 [18414853.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 18;1482(1-2):298-307 [11058770.001]
  • [Cites] Biotechniques. 2001 Mar;30(3):670-5 [11252802.001]
  • [Cites] Science. 2001 Aug 3;293(5531):829-34 [11486081.001]
  • [Cites] Cancer Invest. 2002;20(1):11-23 [11852993.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):737-40 [11920644.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1045-56 [12453413.001]
  • [Cites] Mol Cell Endocrinol. 2003 Apr 28;202(1-2):97-9 [12770737.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):355-66 [14764655.001]
  • [Cites] Cancer Invest. 2004;22(2):312-20 [15199613.001]
  • [Cites] Oncogene. 1989 May;4(5):601-8 [2542864.001]
  • [Cites] J Biol Chem. 1993 May 15;268(14):10425-32 [7683678.001]
  • [Cites] J Biol Chem. 1995 Sep 22;270(38):22565-70 [7545679.001]
  • [Cites] Gut. 1996 Mar;38(3):414-20 [8675096.001]
  • [Cites] Cancer Lett. 1998 Jan 9;122(1-2):209-14 [9464512.001]
  • (PMID = 19188485.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Biomarkers, Tumor; 0 / Fluorescent Dyes; 0 / LCN2 protein, human; 0 / Lipocalins; 0 / Proto-Oncogene Proteins
  • [Other-IDs] NLM/ PMC2675069
  •  go-up   go-down


35. Agarwal A, Covic L, Sevigny LM, Kaneider NC, Lazarides K, Azabdaftari G, Sharifi S, Kuliopulos A: Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther; 2008 Sep;7(9):2746-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.
  • Gene chip and proteomic analyses of tumors and stromal tissue has led to the identification of dozens of candidate tumor and host components potentially involved in tumor-stromal interactions, angiogenesis, and progression of invasive disease.
  • From an initial screen of benign versus malignant patient fluids, we delineated a metalloprotease cascade comprising MMP-14, MMP-9, and MMP-1 that culminates in activation of PAR1, a G protein-coupled protease-activated receptor up-regulated in diverse cancers.
  • In xenograft models of advanced peritoneal ovarian cancer, PAR1-dependent angiogenesis, ascites formation, and metastasis were effectively inhibited by i.p. administration of cell-penetrating pepducins based on the intracellular loops of PAR1.
  • These data provide an in vivo proof-of-concept that targeting the metalloprotease-PAR1 signaling system may be a novel therapeutic approach in the treatment of ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2658-65 [16510585.001]
  • [Cites] Gynecol Oncol. 2006 Mar;100(3):506-10 [16214204.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7766-74 [16885380.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2673-86 [16983145.001]
  • [Cites] J Cell Sci. 2007 Mar 15;120(Pt 6):921-8 [17344429.001]
  • [Cites] Nat Protoc. 2007;2(3):504-11 [17406614.001]
  • [Cites] Nat Immunol. 2007 Dec;8(12):1303-12 [17965715.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12257-62 [10535908.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):369-76 [10831344.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5933-40 [11479236.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):291-8 [11531282.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:463-516 [11687497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):643-8 [11805322.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 22;187(1-2):39-45 [11988310.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2923-8 [12019173.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42 [12165638.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1161-5 [12357249.001]
  • [Cites] Circ Res. 2003 Feb 21;92(3):272-8 [12595338.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36537-46 [12847101.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8716-22 [14647466.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):163-78 [15163296.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7045-9 [15466198.001]
  • [Cites] Int J Cancer. 1994 Jul 1;58(1):50-6 [8014015.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):360-8 [7812969.001]
  • [Cites] J Cell Physiol. 1995 Jun;163(3):510-22 [7775594.001]
  • [Cites] Nat Med. 1996 Apr;2(4):461-2 [8597958.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):30174-80 [8939968.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1457-63 [9338470.001]
  • [Cites] Nat Med. 1998 Aug;4(8):909-14 [9701242.001]
  • [Cites] J Pathol. 1998 Jul;185(3):256-61 [9771478.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1249-56 [9777956.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5321-5 [9850057.001]
  • [Cites] Biochemistry. 1999 Apr 6;38(14):4572-85 [10194379.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:25-39 [10415718.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51148-55 [15381707.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):372-8 [15455382.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):437-48 [15581944.001]
  • [Cites] Cell. 2005 Feb 11;120(3):303-13 [15707890.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):207-8 [15766657.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2686-94 [15814650.001]
  • [Cites] Nat Med. 2005 May;11(5):481-3 [15864312.001]
  • [Cites] Nat Med. 2005 Jun;11(6):661-5 [15880119.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Circulation. 2006 Mar 7;113(9):1244-54 [16505172.001]
  • (PMID = 18790755.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA122992; United States / NHLBI NIH HHS / HL / R01 HL064701-07; United States / NCI NIH HHS / CA / CA122992-02; United States / NHLBI NIH HHS / HL / R01 HL057905-10; United States / NHLBI NIH HHS / HL / HL64701; United States / NHLBI NIH HHS / HL / R01 HL064701; United States / NCI NIH HHS / CA / R01 CA104406; United States / NCI NIH HHS / CA / CA122992; United States / NHLBI NIH HHS / HL / HL064701-07; United States / NCI NIH HHS / CA / CA104406; United States / NHLBI NIH HHS / HL / HL57905; United States / NHLBI NIH HHS / HL / R01 HL057905; United States / NCI NIH HHS / CA / R01 CA122992-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligopeptides; 0 / Receptor, PAR-1; 0 / Taxoids; 15H5577CQD / docetaxel; EC 3.4.- / Metalloproteases
  • [Other-IDs] NLM/ NIHMS68708; NLM/ PMC2735132
  •  go-up   go-down


36. Young RH: Dusting off another shelf: further comments on classic gynecologic pathology books of yesteryear. Int J Gynecol Pathol; 2005 Jan;24(1):100-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each of them emphasizes the time-honored problem of mimicry of malignancy by diverse benign lesions or even aspects of normal histology.
  • The other three books considered are all devoted largely or exclusively to the ovary: Ovarian Tumors by Hans Selye, Ovarian Neoplasms, Morphology, and Classification by Karel Motlik, and Special Tumors of Ovary and Testis and Related Extragonadal Lesions by Gunnar Teilum.
  • A number of aspects of the histopathology of ovarian tumors that have been emphasized in recent years are noted in Selye's book. Dr.
  • Motlik's book presents a very high quality consideration of the differential diagnosis of ovarian tumors.
  • Teilum's book contains a masterful account of the histopathology of germ cell tumors emphasizing a neoplasm with which his name will always be associated, the yolk sac tumor (endodermal sinus tumor).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626924.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA: Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer; 2007 Sep 15;110(6):1264-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
  • BACKGROUND: The authors recently reported on the role of cyclin E in differentiating ovarian/primary peritoneal carcinoma from malignant peritoneal mesothelioma using gene expression arrays.
  • In the current study, they analyzed the expression of low-molecular weight (LMW) forms of cyclin E in ovarian carcinoma, malignant mesothelioma, and benign reactive effusions.
  • METHODS: Cyclin E protein expression was analyzed in 98 effusions (72 ovarian carcinomas, 14 malignant mesotheliomas, and 12 reactive specimens) using immunoblotting.
  • Sixty-two ovarian carcinoma effusions were studied further for cyclin E expression using immunohistochemistry.
  • The correlations between cyclin E expression in ovarian carcinoma and clinical parameters, including chemotherapy response, were analyzed.
  • RESULTS: LMW forms of cyclin E were identified in 54 of 72 ovarian carcinoma effusions (75%) compared with 1 of 14 malignant mesothelioma effusions (7%) and 1 of 12 reactive effusions (8%) (P < .001).
  • Their presence in ovarian carcinoma was associated with a higher percentage of cyclin E-positive cells (P = .001) and increased staining intensity (P < .001) using immunohistochemistry.
  • CONCLUSIONS: LMW forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and were associated with increased protein expression using immunohistochemistry.
  • The expression of LMW cyclin E forms was not associated with chemotherapy response, although it may be a marker of aggressive disease in patients with metastatic ovarian carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / chemistry. Carcinoma / mortality. Cyclin E / analysis. Mesothelioma / chemistry. Mesothelioma / mortality. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / mortality


38. Jeoung HY, Choi HS, Lim YS, Lee MY, Kim SA, Han SJ, Ahn TG, Choi SJ: The efficacy of sonographic morphology indexing and serum CA-125 for preoperative differentiation of malignant from benign ovarian tumors in patients after operation with ovarian tumors. J Gynecol Oncol; 2008 Dec;19(4):229-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of sonographic morphology indexing and serum CA-125 for preoperative differentiation of malignant from benign ovarian tumors in patients after operation with ovarian tumors.
  • OBJECTIVE: To evaluate the value of sonographic morphology indexing (MI) system and serum CA-125 levels in the assessment of the malignancy risk in patients with ovarian tumors.
  • METHODS: From September 2000 to July 2006, 202 patients who underwent surgery for ovarian tumors were reviewed retrospectively.
  • The association of the final pathologic diagnosis with the MI score and serum CA-125 level were examined.
  • RESULTS: There were 26 malignant tumors out of 141 ovarian tumors with a MI >/=5 (18%).
  • There were 22 malignant tumors out of 54 ovarian tumors with serum CA-125 >30 u/ml (41%).
  • CONCLUSION: The sonographic MI system is an accurate and simple method to differentiate a malignant tumor from a benign ovarian tumor.
  • The accuracy of the sonographic MI system improved when the serum CA-125 level was considered and ovarian teratomas were excluded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1985 May;155(2):477-8 [3885313.001]
  • [Cites] Int J Gynecol Pathol. 1982;1(1):3-16 [7184889.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):46-50 [14529661.001]
  • [Cites] Radiol Clin North Am. 2003 Jul;41(4):799-811 [12899493.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2001 May;96(1):80-4 [11311766.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):475-90 [11259710.001]
  • [Cites] CA Cancer J Clin. 1999 Sep-Oct;49(5):297-320 [11198956.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):454-9 [10831359.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):410-2 [10831351.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):350-6 [10831341.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Radiology. 1999 Jul;212(1):19-27 [10405715.001]
  • [Cites] Gynecol Oncol. 1998 Apr;69(1):3-7 [9570990.001]
  • [Cites] Obstet Gynecol. 1995 Jan;85(1):48-52 [7800323.001]
  • [Cites] Gynecol Oncol. 1994 Nov;55(2):174-8 [7959280.001]
  • [Cites] Gynecol Oncol. 1993 Oct;51(1):7-11 [8244178.001]
  • [Cites] Obstet Gynecol. 1991 Jul;78(1):70-6 [2047071.001]
  • [Cites] Gynecol Oncol. 1990 Oct;39(1):69-71 [2227575.001]
  • [Cites] Br J Obstet Gynaecol. 1990 Oct;97(10):922-9 [2223684.001]
  • (PMID = 19471578.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676475
  • [Keywords] NOTNLM ; CA-125 antigen / ROC curve / Teratoma / Ultrasonogram (morphology indexing)
  •  go-up   go-down


39. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M: CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer; 2005 Sep-Oct;15(5):679-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.
  • CA125 is currently the most widely used tumor marker for ovarian epithelial cancer.
  • The aim of this article is to provide guidelines for the routine clinical use of CA125 in patients with ovarian cancer.
  • Due to lack of sensitivity for stage I disease and lack of specificity, CA125 is of little value in the detection of early ovarian cancer.
  • At present, therefore, CA125, either alone or in combination with other modalities, cannot be recommended for screening for ovarian cancer in asymptomatic women outside the context of a randomized controlled trial.
  • Preoperative levels in postmenopausal women, however, may aid the differentiation of benign and malignant pelvic masses.
  • Serial levels during chemotherapy for ovarian cancer are useful for assessing response to treatment.
  • CA125 is the ovarian cancer marker against which new markers for this malignancy should be judged.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Diagnosis, Differential. Europe. Female. Follow-Up Studies. Humans. Middle Aged. Prognosis. Societies, Scientific

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174214.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


40. Erdoğan N, Ozçelik B, Serin IS, Akgün M, Oztürk F: Doppler ultrasound assessment and serum cancer antigen 125 in the diagnosis of ovarian tumors. Int J Gynaecol Obstet; 2005 Nov;91(2):146-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doppler ultrasound assessment and serum cancer antigen 125 in the diagnosis of ovarian tumors.
  • OBJECTIVE: To differentiate benign from malignant ovarian tumors based on sonographic detection of a solid component.
  • METHOD: Sixty-three women with ovarian masses were evaluated preoperatively by gray scale and power/color Doppler ultrasonographic examination, with specific predefined criteria for the solid component.
  • CONCLUSION: Sonographic evaluation with predefined specific criteria for the detection of a solid tumor component is an accurate method of preoperative discrimination between benign and malignant ovarian tumors.
  • [MeSH-major] Adnexal Diseases / diagnostic imaging. CA-125 Antigen / blood. Ovarian Neoplasms / diagnostic imaging. Ultrasonography, Doppler
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. False Positive Reactions. Female. Humans. Middle Aged. Predictive Value of Tests. Preoperative Care. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083888.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


41. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC: Accuracy of ultrasonography with color Doppler in ovarian tumor: a systematic quantitative review. Int J Gynecol Cancer; 2009 Oct;19(7):1214-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of ultrasonography with color Doppler in ovarian tumor: a systematic quantitative review.
  • A quantitative systematic review was performed to estimate the accuracy ultrasonography with color Doppler in the diagnosis of ovarian tumors.
  • Studies that compared color Doppler ultrasonography with paraffin-embedded sections parameters for the diagnosis of ovarian tumors were included.
  • The diagnostic odds ratio for ovarian cancer and borderline lesions versus benign lesions was 125 (95%CI, 55-283).
  • For malignant ovarian cancer and borderline versus benign lesions the area under the curve was 0.9577.
  • In conclusion, ultrasonography with color Doppler is a useful preoperative test for predicting the diagnosis of pelvic masses.
  • [MeSH-major] Carcinoma / ultrasonography. Ovarian Neoplasms / ultrasonography. Ultrasonography, Doppler, Color / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19823057.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


42. Kato M, Kubota K, Kita J, Shimoda M, Rokkaku K, Inaba N, Fukasawa I, Honma K: Huge mucinous cystadenoma of the pancreas developing during pregnancy: a case report. Pancreas; 2005 Mar;30(2):186-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A tentative diagnosis of ovarian or pancreatic mucinous cystadenoma was made.
  • Histological diagnosis was a benign mucinous cystadenoma.
  • Our case is the third reported of successful resection of the tumor during pregnancy resulting in a healthy infant.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Pancreatic Neoplasms / pathology. Pregnancy Complications, Neoplastic


43. Liu HD, Yan Y, Cao XF, Tan PZ, Wen HX, Lv CM, Li XM, Liu GY: [The expression of a novel estrogen receptor, GPR30, in epithelial ovarian carcinoma and its correlation with MMP-9]. Sheng Li Xue Bao; 2010 Dec 25;62(6):524-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of a novel estrogen receptor, GPR30, in epithelial ovarian carcinoma and its correlation with MMP-9].
  • The aim of the present study is to investigate the expression of a novel estrogen receptor, G protein-coupled receptor 30 (GPR30) and its correlation with matrix metalloproteinases-9 (MMP-9) in epithelial ovarian cancer (EOC).
  • Ovary tissues were obtained from 39 female patients, including 30 cases of EOC and 9 cases of benign ovarian tumor.
  • Four normal ovary tissues were used as control.
  • The results showed that GPR30 overexpression rate in EOC cases was significantly higher than those in benign ovarian tumor and normal ovary cases.
  • Whereas MMP-9 overexpression rate in EOC cases was significantly higher than that in normal ovary cases, without any difference to that in benign ovarian tumor cases.
  • These results suggest that GPR30 may be involved in the invasion and metastasis of EOC, being a potential index of EOC early diagnosis and malignancy grade prediction.
  • [MeSH-major] Biomarkers / metabolism. Matrix Metalloproteinase 9 / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Receptors, Estrogen / metabolism. Receptors, G-Protein-Coupled / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21170498.001).
  • [ISSN] 0371-0874
  • [Journal-full-title] Sheng li xue bao : [Acta physiologica Sinica]
  • [ISO-abbreviation] Sheng Li Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / GPER protein, human; 0 / Receptors, Estrogen; 0 / Receptors, G-Protein-Coupled; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


44. Sonoda K, Miyamoto S, Yotsumoto F, Yagi H, Nakashima M, Watanabe T, Nakano H: Clinical significance of RCAS1 as a biomarker of ovarian cancer. Oncol Rep; 2007 Mar;17(3):623-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of RCAS1 as a biomarker of ovarian cancer.
  • Expression of RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is associated with advanced disease of various malignancies including ovarian cancer.
  • Although RCAS1 can induce apoptosis in normal peripheral lymphocytes, its clinical significance and biologic function in ovarian cancer patients are unclear.
  • Here, we evaluated serum RCAS1 concentrations to clarify its clinical significance and biologic activity in ovarian cancer.
  • Via ELISA, we measured serum RCAS1 concentrations in samples from 75 healthy blood donors and 97 patients, 36 with ovarian benign tumor and 61 with ovarian cancer.
  • Ovarian cancer patients had significantly higher serum RCAS1 concentrations than did healthy blood donors and ovarian tumor patients (P<0.05).
  • RCAS1 level was significantly different according to histologic subtype for both ovarian tumor and cancer patients (P=0.0266 and 0.0074, respectively).
  • RCAS1 may be a biomarker of ovarian cancer by virtue of its ability to predict results of treatment and inhibit immune cell growth.
  • [MeSH-major] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273743.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / EBAG9 protein, human
  •  go-up   go-down


45. Drenberg CD, Livingston S, Chen R, Kruk PA, Nicosia SV: Expression of Semaphorin 3F and Its Receptors in Epithelial Ovarian Cancer, Fallopian Tubes, and Secondary Müllerian Tissues. Obstet Gynecol Int; 2009;2009:730739
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Semaphorin 3F and Its Receptors in Epithelial Ovarian Cancer, Fallopian Tubes, and Secondary Müllerian Tissues.
  • While semaphorins and their receptors appear to play a role in tumor carcinogenesis, little is known about the role of semaphorin 3F (S3F) in epithelial ovarian cancer (EOC) development.
  • We analyzed the immunohistological expression of S3F, NP-2, and NP-1 in clinical specimens of normal ovaries (N), benign cystadenomas (Cy), well-differentiated adenocarcinomas (WD), poorly-differentiated adenocarcinomas (PD), inclusion cysts (IC), paraovarian cysts (PC), and fallopian tubes (FT).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):939-50 [10702410.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1414-25 [17010410.001]
  • [Cites] Neoplasia. 2005 May;7(5):457-65 [15967098.001]
  • [Cites] Neoplasia. 2005 Feb;7(2):180-9 [15802023.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1260-71 [15520858.001]
  • [Cites] Cell. 1999 Oct 1;99(1):71-80 [10520995.001]
  • [Cites] Cell. 1999 Oct 1;99(1):59-69 [10520994.001]
  • [Cites] Cell. 1998 Mar 20;92(6):735-45 [9529250.001]
  • [Cites] Neuron. 1998 Nov;21(5):1079-92 [9856463.001]
  • [Cites] Cell. 1997 Aug 22;90(4):753-62 [9288754.001]
  • [Cites] Cell. 1997 Aug 22;90(4):739-51 [9288753.001]
  • [Cites] Am J Obstet Gynecol. 2004 Sep;191(3):718-32 [15467531.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1008-15 [14871832.001]
  • [Cites] J Pathol. 2003 Jul;200(3):336-47 [12845630.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):83-92 [12659673.001]
  • [Cites] Mech Dev. 2003 Mar;120(3):385-96 [12591607.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2637-43 [11980661.001]
  • [Cites] Neuron. 2001 Feb;29(2):429-39 [11239433.001]
  • [Cites] Lancet Oncol. 2008 Dec;9(12):1191-7 [19038766.001]
  • (PMID = 20041133.001).
  • [ISSN] 1687-9597
  • [Journal-full-title] Obstetrics and gynecology international
  • [ISO-abbreviation] Obstet Gynecol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2796214
  •  go-up   go-down


46. Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, Mapes JP, Mansfield BC: Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2872-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer.
  • Ovarian cancer is the deadliest gynecologic cancer in the United States.
  • The population, weighted with early-stage cancers to assess biomarker value for early detection, contained all stages of ovarian cancer and common benign gynecologic conditions.
  • The panel of serum molecules was assayed using rigorously qualified, high-throughput, multiplexed immunoassays and evaluated for their independent ovarian cancer diagnostic potential.
  • Seventy-seven biomarkers were dysregulated in the ovarian cancer samples, although cancer antigen 125, C-reactive protein, epidermal growth factor receptor, interleukin 10, interleukin 8, connective tissue growth factor, haptoglobin, and tissue inhibitor of metalloproteinase 1 stood out as the most informative.
  • In this study, using a large sample cohort, we show that some of the reported ovarian cancer biomarkers are more robust than others, and we identify additional informative candidates.
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / immunology


47. Wang Y, Wang Y, Cheng C, Ji Y, Zhao Y, Zou L, Shen A: Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma. J Cancer Res Clin Oncol; 2009 Jul;135(7):951-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma.
  • PURPOSE: The aim of the present study was to examine whether Jab1 expression is correlated with p27 protein and its phosphorylation status as well as how it might be clinically relevant in epithelial ovarian carcinoma.
  • Using ovarian carcinoma cell line HO-8910 to confirm and extend the findings.
  • METHODS: Immunohistochemical and Western blot analysis were done in 70 cases of epithelial ovarian cacinoma and HO-8910 cells.
  • RESULTS: Jab1 overexpression was detected in 84.3% (59 of 70) of malignant tumors and 31.6% (6 of 19) of benign tumors.
  • A positive correlation between Jab1 and cytoplasmic p27 as well as Ser10 phosphorylated p27 was found in malignant ovarian tumors.
  • CONCLUSIONS: Jab1, as a negative regulator of p27, may be associated with the progression and prognosis of epithelial ovarian tumors.
  • [MeSH-major] Carcinoma in Situ / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Ovarian Neoplasms / metabolism. Peptide Hydrolases / metabolism
  • [MeSH-minor] Adult. Aged. Cyclin-Dependent Kinase 2 / metabolism. Disease Progression. Female. Humans. Middle Aged. Phosphorylation. Prognosis. Protein Binding. Protein-Serine-Threonine Kinases / metabolism. Serine / metabolism. Transfection. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. L-SERINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1997 Sep 1;16(17):5334-44 [9311993.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):10-7 [10699961.001]
  • [Cites] Trends Cell Biol. 2001 Oct;11(10 ):420-6 [11567875.001]
  • [Cites] Curr Opin Cell Biol. 2000 Dec;12(6):676-84 [11063931.001]
  • [Cites] Nature. 1999 Mar 11;398(6723):160-5 [10086358.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25146-54 [10831586.001]
  • [Cites] Nat Med. 2002 Oct;8(10 ):1145-52 [12244301.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5652-9 [14654548.001]
  • [Cites] Science. 1995 Aug 4;269(5224):682-5 [7624798.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 1;347(3):601-7 [16842750.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2977-81 [12782606.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1136-44 [12244303.001]
  • [Cites] Genes Dev. 1997 Jun 1;11(11):1464-78 [9192873.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8132-41 [15623586.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8581-9 [16951171.001]
  • [Cites] Cancer J. 2002 May-Jun;8 Suppl 1:S22-30 [12075699.001]
  • [Cites] J Biol Chem. 2002 Jan 18;277(3):2302-10 [11704659.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17 ):14355-8 [11889117.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2635-43 [12050228.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1153-60 [12244302.001]
  • [Cites] Cell. 1994 Jul 15;78(1):59-66 [8033212.001]
  • [Cites] EMBO Rep. 2001 Feb;2(2):96-101 [11258719.001]
  • [Cites] Nature. 1998 Nov 12;396(6707):177-80 [9823898.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4130-5 [11751512.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1672-7 [8939849.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):453-7 [8837781.001]
  • [Cites] EMBO J. 2001 Dec 3;20(23 ):6672-82 [11726503.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6583-91 [11522658.001]
  • [Cites] Oncology. 2003;65(4):355-62 [14707456.001]
  • (PMID = 19139918.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 452VLY9402 / Serine; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 3.4.- / Peptide Hydrolases; EC 3.4.-.- / COPS5 protein, human
  •  go-up   go-down


48. Marret H, Sauget S, Giraudeau B, Body G, Tranquart F: Power Doppler vascularity index for predicting malignancy of adnexal masses. Ultrasound Obstet Gynecol; 2005 May;25(5):508-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the performance of a power Doppler vascularity index in the preoperative diagnosis of ovarian malignancy.
  • The tumor vascularity index (power Doppler index, PDI) was determined by quantification of the number of pixels in a defined region of interest according to the formula: number of colored pixels/(total number of pixels minus the number of pixels in the fluid or avascular areas).
  • It was estimated on selected frames of the tumors using an in-house color-quantifying program added to MATLAB 6.0 software.
  • A subjective visual score of power Doppler signals in the tumor was used to classify it as having low, moderate or high vascularity.
  • RESULTS: Histology identified 23 malignant and 78 benign lesions.
  • The PDI was considerably higher in malignant than in benign lesions (0.34 +/- 0.04 vs. 0.12 +/- 0.06; P < 0.001).
  • The PDI cut-off value to differentiate malignant from benign tumors was set at 0.265 (26.5% of the tumor being colored).
  • Logistic regression demonstrated that PDI was the best parameter for differentiating between malignant and benign tumors.
  • CONCLUSION: The power Doppler vascularity index obtained using customized color quantifying software has high diagnostic value in discriminating between benign and malignant adnexal masses.
  • [MeSH-major] Adnexa Uteri / ultrasonography. Adnexal Diseases / ultrasonography. Ovarian Neoplasms / ultrasonography. Ultrasonography, Doppler / methods
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Diagnosis, Differential. Female. Humans. Middle Aged. Ovary / physiopathology. Ovary / ultrasonography. Pilot Projects. Prospective Studies. ROC Curve. Regional Blood Flow. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846763.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Olgac S, Hutchinson B, Tickoo SK, Reuter VE: Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma. Mod Pathol; 2006 Feb;19(2):218-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
  • Metanephric adenoma (MA), a well-described renal neoplasm, usually behaves in a benign fashion.
  • It may have areas that are morphologically similar to papillary renal cell carcinoma (RCC) type, or epithelial (tubular predominant) type Wilms' tumor.
  • Alpha-methylacyl-CoA racemase (AMACR), a molecular marker for prostate carcinoma, has subsequently been found to be overexpressed in breast, colorectal and ovarian cancers, among others.
  • Recent microarray analysis of renal tumors has shown an increase of AMACR mRNA levels in papillary RCC but not in other subtypes.
  • We investigated the utility of immunohistochemical staining for AMACR, cytokeratin 7(CK7), CD57 and WT1 to differentiate between the above-mentioned three neoplasms.
  • Immunohistochemical stains were performed on paraffin-embedded tissue sections from 25 papillary RCC, 10 MAs and eight Wilms' tumors.
  • AMACR was positive in one (10%) of 10 MAs and 24 (96%) of 25 papillary RCC, while it was negative in all Wilms' tumors.
  • CK7 was positive in 20 of 25 papillary RCCs, focally positive in one Wilms' tumor and was negative in all MAs.
  • CD57 was positive in all six MAs that were stained, focally positive in one of 25 papillary RCC and one of eight Wilms' tumors.
  • WT1 was positive in seven of 10 MAs, three of 25 papillary RCCs and all eight Wilms' tumors.
  • In conclusion, diffuse and strong immunoreactivity for AMACR may be useful in differentiating papillary RCC from MA but a panel which includes AMACR, CK7 and CD57 is better in this differential diagnosis.
  • AMACR is not helpful in differentiating MA from Wilms' tumor, but CD57 is helpful in this differential diagnosis.
  • WT1 may be useful in separating Wilms' tumor from MA and papillary RCC but is not helpful in differentiating MA from papillary RCC.
  • [MeSH-major] Adenoma / pathology. Biomarkers, Tumor / analysis. Kidney Neoplasms / pathology. Racemases and Epimerases / analysis
  • [MeSH-minor] Antigens, CD57 / analysis. Carcinoma, Papillary / enzymology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / enzymology. Carcinoma, Renal Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-7. Keratins / analysis. WT1 Proteins / analysis. Wilms Tumor / enzymology. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424894.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD57; 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / WT1 Proteins; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


50. Vaysse C, Delsol M, Carfagna L, Bouali O, Combelles S, Lemasson F, Le Mandat A, Castex MP, Pasquet M, Moscovici J, Guitard J, Pienkowski C, Rubie H, Galinier P, Vaysse P: Ovarian germ cell tumors in children. Management, survival and ovarian prognosis. A report of 75 cases. J Pediatr Surg; 2010 Jul;45(7):1484-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian germ cell tumors in children. Management, survival and ovarian prognosis. A report of 75 cases.
  • BACKGROUND/PURPOSE: The aims of this study were to evaluate survival and ovarian prognosis in patients treated for ovarian germ cell tumor (OGCT) and to propose a decision-making protocol.
  • Tumor characteristics were assessed by tumor markers, imaging, and pathology.
  • Tumors were benign in 58 cases and malignant in 17 cases.
  • The average of the largest diameter of benign OGCT was significantly lower than that of malignant OGCT (76.5 +/- 49 mm versus 169 +/- 54 mm, P < .0001).
  • Ovarian-sparing tumorectomy was carried out in 27 benign OGCT; 23 (85%) preserved ovaries were follicular.
  • CONCLUSIONS: In our series, both benign and malignant OGCTs have a good prognosis.
  • A 75-mm cutoff size is proposed as an important criterion to preoperatively differentiate between benign and malignant tumors.
  • In benign OGCT, ovarian-sparing tumorectomy leads to preserve ovaries in approximately 85% of cases, and in malignant OGCT, high survival rate has been obtained.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Biomarkers, Tumor. Child. Child, Preschool. Female. France. Humans. Infant. Ovariectomy. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20638529.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


51. Noske A, Faggad A, Wirtz R, Darb-Esfahani S, Sehouli J, Sinn B, Nielsen FC, Weichert W, Buckendahl AC, Röske A, Müller B, Dietel M, Denkert C: IMP3 expression in human ovarian cancer is associated with improved survival. Int J Gynecol Pathol; 2009 May;28(3):203-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMP3 expression in human ovarian cancer is associated with improved survival.
  • Although IMP3 expression has been well studied in mouse and human fetal and adult gonads, its role in ovarian cancer is unknown.
  • We investigated the expression of IMP3 at protein and mRNA levels in a cohort of primary ovarian carcinomas and in 11 ovarian cancer cell lines.
  • Western blot analysis revealed an expression of IMP3 in all ovarian cancer cell lines and immunohistochemistry demonstrated a positive cytoplasmic staining in 32 of 68 carcinomas (47%).
  • In contrast, epithelium of borderline tumors, as well as, benign ovarian lesions and normal ovaries exhibited only weak or no IMP3 expression.
  • To confirm these findings, we further determined IMP3 mRNA expression in 43 ovarian cancer specimens by real time quantitative reverse transcription-polymerase chain reaction.
  • Our results demonstrate that IMP3 is expressed in a subpopulation of ovarian cancer and a marker of good prognosis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / pathology. RNA-Binding Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Female. Gene Expression. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620937.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


52. Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA, Harrington KM, Skubitz AP: Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol; 2010 Nov;134(5):835-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker.
  • Early detection of ovarian cancer is difficult owing to the lack of specific and sensitive tests available.
  • Previously, we found expression of nectin 4 to be increased in ovarian cancer compared with normal ovaries.
  • Reverse transcriptase-polymerase chain reaction (RT-PCR) and quantitative RT-PCR validated the overexpression of nectin 4 messenger RNA in ovarian cancer compared with normal ovarian cell lines and tissues.
  • Protein levels of nectin 4 were elevated in ovarian cancer cell lines and tissue compared with normal ovarian cell lines as demonstrated by Western immunoblotting, flow cytometry, and immunohistochemical staining of tissue microarray slides.
  • In patients with benign gynecologic diseases with high serum CA125 levels, nectin 4 was not detected in the majority of cases, suggesting that nectin 4 may serve as a potential biomarker that helps discriminate benign gynecologic diseases from ovarian cancer in a panel with CA125.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2009 Apr;113(1):143-8 [19135710.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1239-51 [18602670.001]
  • [Cites] Cancer Res. 2009 Aug 15;69(16):6694-703 [19679554.001]
  • [Cites] Am J Clin Pathol. 2009 Dec;132(6):846-56 [19926575.001]
  • [Cites] Clin Chem. 2010 Feb;56(2):327-9 [20110452.001]
  • [Cites] Electrophoresis. 2010 Jan;31(4):599-610 [20162585.001]
  • [Cites] Gene. 2000 Sep 19;255(2):347-55 [11024295.001]
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):43205-15 [11544254.001]
  • [Cites] Cancer Treat Res. 2002;107:61-97 [11775462.001]
  • [Cites] Mol Cell Probes. 2002 Apr;16(2):99-110 [12030760.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27006-13 [12011057.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Feb 28;302(1):61-6 [12593848.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):1-10 [14968412.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):397-414 [15277215.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):513-21 [15363801.001]
  • [Cites] Lab Invest. 1990 Jul;63(1):132-6 [2374399.001]
  • [Cites] FEBS Lett. 1998 Apr 24;426(3):386-91 [9600272.001]
  • [Cites] Semin Cancer Biol. 1999 Apr;9(2):117-24 [10202133.001]
  • [Cites] Biol Chem. 2004 Oct;385(10):885-92 [15551862.001]
  • [Cites] Semin Cell Dev Biol. 2004 Dec;15(6):643-56 [15561584.001]
  • [Cites] Mol Ther. 2004 Dec;10(6):1032-42 [15564135.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19543-50 [15784625.001]
  • [Cites] Clin Exp Metastasis. 2004;21(8):685-97 [16035613.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4319-28 [16618757.001]
  • [Cites] Oncogene. 2006 Aug 24;25(37):5085-102 [16607281.001]
  • [Cites] BMC Cancer. 2007;7:73 [17474988.001]
  • [Cites] Curr Opin Cell Biol. 2007 Oct;19(5):593-602 [17942295.001]
  • [Cites] J Clin Pathol. 2008 Feb;61(2):152-63 [17704261.001]
  • [Cites] J Biomol Screen. 2008 Jan;13(1):1-8 [18040052.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):161-74 [18317227.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • (PMID = 20959669.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106878-05; United States / NCI NIH HHS / CA / R01 CA106878; United States / NCI NIH HHS / CA / R01 CA106878-05; United States / NCI NIH HHS / CA / R01-CA106878
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / LNIR protein, human
  • [Other-IDs] NLM/ NIHMS264396; NLM/ PMC3042138
  •  go-up   go-down


53. Loar P, Wahl H, Kshirsagar M, Gossner G, Griffith K, Liu JR: Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol; 2010 Apr;202(4):371.e1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells.
  • OBJECTIVE: Up-regulation of glycolysis has been demonstrated in multiple tumor types and is believed to originate as an adaptive response to the selective pressure of the tumor microenvironment.
  • We hypothesized that ovarian cancer cells are dependent on the glycolytic pathway for adenosine triphosphate generation and that this phenotype could be exploited for therapeutic intervention.
  • STUDY DESIGN: Expression of glucose transporter 1 (Glut1), phosphorylated protein kinase B (pPKB/pAkt), and phosphorylated mammalian target of rapamycin (pmTOR) was assessed in ovarian carcinoma tumors and cell lines.
  • RESULTS: Ovarian carcinoma cells overexpress Glut1, pAkt, and pmTOR compared with benign ovarian epithelial cells.
  • 2-deoxyglucose and rapamycin markedly enhance apoptotic and nonapoptotic cell death in ovarian cancer cells.
  • CONCLUSION: The glycolytic phenotype of ovarian cancer cells can be targeted for therapeutic intervention.
  • Combined treatment modalities that target multiple cellular pathways hold promise for the treatment of chemoresistant ovarian cancer cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Cisplatin / pharmacology. Glycolysis / drug effects. Ovarian Neoplasms
  • [MeSH-minor] Antibiotics, Antineoplastic / pharmacology. Antimetabolites / pharmacology. Cell Line, Tumor. Deoxyglucose / pharmacology. Female. Glucose Transporter Type 1 / metabolism. Humans. Intracellular Signaling Peptides and Proteins / metabolism. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Sirolimus / pharmacology. TOR Serine-Threonine Kinases

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20138251.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites; 0 / Antineoplastic Agents; 0 / Glucose Transporter Type 1; 0 / Intracellular Signaling Peptides and Proteins; 0 / SLC2A1 protein, human; 9G2MP84A8W / Deoxyglucose; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; Q20Q21Q62J / Cisplatin; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


54. Daneshbod Y, Daneshbod K, Rasekhi AR, Mosayebi Z, Negahban S, Hodjati SR, Bedayat GR, Ganjei-Azar P: Cytologic differentiation of struma ovarii from other ovarian neoplasms. Acta Cytol; 2008 Jan-Feb;52(1):72-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic differentiation of struma ovarii from other ovarian neoplasms.
  • OBJECTIVE: To present the cytologic findings of struma ovarii and value of cytology and immunocytochemistry (ICC) using thyroglobulin (TGB) and thyroid transcription factor-1 (TTF-1) in evaluation of this unusual ovarian neoplasm, together with the diagnostic pitfalls.
  • RESULTS: The cases were divided in to 3 groups: group 1--diagnosis of struma ovarii was made by cytology and confirmed by ICC (1 case); group 2--diagnosis was suggestive on cytology or cell block and confirmed by ICC staining (4 cases); group 3--on cytologic diagnosis indistinguishable from other cystic ovarian neoplasms (2 cases).
  • Cytologic findings were typically colloid with mosaic pattern, follicles, follicular cells only, sheets of follicular cells, both colloid and follicular cells, proteinaceous background or degenerated epithelial cells indistinguishable from other cystic ovarian neoplasms.
  • CONCLUSION: Cytologic findings of struma ovarii are distinct enough to be suggested intraoperatively, and ICC for TGB or TTF-1 is a valuable tool for preoperative fine needle aspiration biopsy and intraoperative diagnosis of this benign ovarian neoplasm.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Ovarian Neoplasms / diagnosis. Struma Ovarii / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Nuclear Proteins / metabolism. Thyroglobulin / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323278.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


55. Garedew A, Kämmerer U, Singer D: Respiratory response of malignant and placental cells to changes in oxygen concentration. Respir Physiol Neurobiol; 2009 Feb 28;165(2-3):154-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, we compared the respiratory responses of different malignant cell types, maternal and foetal placental leucocytes, and benign cells by incubating them under a gradient of pO2, from saturation to hypoxia, in a high resolution respirometer.
  • The malignant cells and foetal leucocytes showed higher rates of mitochondrial oxygen uptake compared to the benign cells and maternal leucocytes, respectively.
  • On the other hand, the JO2 of the benign cells declined with the decrease in [O2] from 200 to 40 microM and <or=10 microM.
  • [MeSH-major] Breast Neoplasms / metabolism. Leukocytes / metabolism. Oxygen / pharmacology. Oxygen Consumption / physiology. Placenta / cytology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Hypoxia / physiology. Cell Line, Tumor. Cell Respiration / physiology. Endothelial Cells / cytology. Endothelial Cells / metabolism. Female. Fetus / cytology. Humans. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Umbilical Veins / cytology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041734.001).
  • [ISSN] 1569-9048
  • [Journal-full-title] Respiratory physiology & neurobiology
  • [ISO-abbreviation] Respir Physiol Neurobiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


56. Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, Tognon G, Ragnoli M, Santin AD, Gion M, Pecorelli S, Ravaggi A: Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. Int J Gynecol Cancer; 2009 Aug;19(6):1015-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response.
  • INTRODUCTION: Kallikrein-related peptidases are secreted serine proteases that exert stimulatory or inhibitory effects on tumor progression.
  • A recent study demonstrated that kallikrein-related peptidase 5 (KLK5) concentration is elevated in serum of patients with ovarian carcinoma.
  • At the moment, the presence of KLK5 in other ovarian pathological lesions is not clearly determined.
  • METHODS: In this study, we examined KLK5 levels and antibody (IgG and IgM) response to KLK5 in the serum of 50 healthy women, 50 patients with benign pelvic masses, 17 patients with ovarian borderline tumors, and 50 patients with ovarian carcinomas, using 3 enzyme-linked immunosorbent assay tests available in-house.
  • RESULTS: At 95% specificity on healthy controls, 52% of patients with ovarian carcinoma showed high serum KLK5 (sKLK5) levels, whereas patients with benign pathological lesions or borderline tumors showed almost undetectable sKLK5 levels.
  • Moreover, sKLK5 levels were positively associated to International Federation of Gynaecologists and Obstetricians stage suggesting a possible role of sKLK5 in ovarian cancer progression.
  • Our results about humoral response showed elevated levels of KLK5-specific antibodies in 20% of patients with benign masses, 26% of patients with borderline tumors, and 36% of patients with ovarian carcinomas when compared with healthy controls.
  • CONCLUSIONS: In conclusion, our results showed that KLK5 is a potential new biomarker to be used in combination with other biomarkers for ovarian cancer detection.
  • [MeSH-major] Carcinoma / immunology. Immunity, Humoral. Kallikreins / blood. Kallikreins / immunology. Ovarian Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Neoplasm / analysis. Antibodies, Neoplasm / blood. Biomarkers, Tumor / blood. Biomarkers, Tumor / immunology. Case-Control Studies. Female. Humans. Immunoassay / methods. Middle Aged. ROC Curve. Retrospective Studies. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820362.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 5, human
  •  go-up   go-down


57. Levy AD, Arnáiz J, Shaw JC, Sobin LH: From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics; 2008 Mar-Apr;28(2):583-607; quiz 621-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation.
  • Primary peritoneal tumors are uncommon lesions that arise from the mesothelial or submesothelial layers of the peritoneum.
  • Primary malignant mesothelioma, multicystic mesothelioma, primary peritoneal serous carcinoma, leiomyomatosis peritonealis disseminata, and desmoplastic small round cell tumor are the most prominent of these rare lesions.
  • Multicystic mesothelioma occurs most frequently in women and has benign or indolent biologic behavior in the majority of patients.
  • It is histologically identical to ovarian serous carcinoma and may be indistinguishable from metastatic ovarian carcinoma at imaging studies.
  • Leiomyomatosis peritonealis disseminata is a rare, benign proliferative process that also occurs exclusively in women and is characterized by multiple smooth muscle nodules throughout the peritoneum.
  • Desmoplastic small round cell tumor is a highly aggressive malignancy of unknown origin that occurs most often in the peritoneal cavity of young men.
  • This unusual group of tumors is linked together by a common site of origin and imaging manifestations that mimic those of peritoneal carcinomatosis.
  • Knowledge of the spectrum of imaging findings in this group of primary peritoneal tumors, along with their clinical and pathologic characteristics, is important in the evaluation of patients with diffuse peritoneal disease.
  • [MeSH-major] Diagnostic Imaging. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Contrast Media. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / pathology. Diagnosis, Differential. Fibrosis / diagnosis. Fibrosis / pathology. Humans. Leiomyomatosis / diagnosis. Leiomyomatosis / pathology. Mesothelioma / diagnosis. Mesothelioma / pathology. Peritoneum / anatomy & histology. Peritoneum / pathology

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349460.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 55
  •  go-up   go-down


58. Exacoustos C, Romanini ME, Rinaldo D, Amoroso C, Szabolcs B, Zupi E, Arduini D: Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol; 2005 Jan;25(1):50-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative sonographic features of borderline ovarian tumors.
  • OBJECTIVE: To determine the sonographic findings that distinguish borderline ovarian tumors (BOT) from both benign and invasive malignant tumors, thus allowing conservative treatment and laparoscopic management of these tumors.
  • We compared these findings with those of 337 patients with benign ovarian tumors and those of 82 patients with invasive malignant ovarian tumors.
  • The presence of papillae, defined as a small number of solid tissue projections, 1-15 mm in height and 1-10 mm in width (base) and length (base), into the cyst cavity from the cyst wall, was significantly more frequent in BOT (48%) than it was in benign (4%) and invasive (4%) malignant tumors.
  • Intracystic solid tissue (> 15 mm in height or > 10 mm in width or length) was observed in 48% of invasive malignant masses but in only 18% of BOT and in 7% of benign tumors (P < 0.001).
  • [MeSH-major] Ovarian Neoplasms / surgery. Ovarian Neoplasms / ultrasonography. Preoperative Care / methods
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / ultrasonography. Adolescent. Adult. Aged. Aged, 80 and over. Child. Cystadenoma, Serous / pathology. Cystadenoma, Serous / surgery. Cystadenoma, Serous / ultrasonography. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Invasiveness. Postmenopause. Premenopause. Retrospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 ISUOG.
  • (PMID = 15619309.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Mangioni S, Viganò P, Florio P, Borghi O, Vignali M, Petraglia F, Di Blasio AM: Effect of activin A on tumor necrosis factor-alpha/intercellular adhesion molecule-1 pathway in endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol; 2005 Dec 1;123(2):218-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of activin A on tumor necrosis factor-alpha/intercellular adhesion molecule-1 pathway in endometrial stromal cells.
  • In the present study we investigated the effects of activin A and inhibin A in modulating the tumor necrosis factor (TNF)-alpha/intercellular adhesion molecule (ICAM)-1 system in cultured human endometrial stromal cells.
  • STUDY DESIGN: Endometrial samples were obtained from 34 reproductive age women undergoing laparoscopy for benign ovarian cysts or infertility.
  • [MeSH-major] Activins / pharmacology. Endometrium / drug effects. Immunologic Factors / pharmacology. Inhibin-beta Subunits / pharmacology. Intercellular Adhesion Molecule-1 / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893868.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interleukin-1; 0 / Tumor Necrosis Factor-alpha; 0 / activin A; 0 / inhibin A; 104625-48-1 / Activins; 126547-89-5 / Intercellular Adhesion Molecule-1; 57285-09-3 / Inhibins; 93443-12-0 / Inhibin-beta Subunits
  •  go-up   go-down


60. Jevremovic D, Lager DJ, Lewin M: Cystic nephroma (multilocular cyst) and mixed epithelial and stromal tumor of the kidney: a spectrum of the same entity? Ann Diagn Pathol; 2006 Apr;10(2):77-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic nephroma (multilocular cyst) and mixed epithelial and stromal tumor of the kidney: a spectrum of the same entity?
  • The recently described mixed epithelial and stromal tumor (MEST) of the kidney and adult cystic nephroma (CN) (multilocular cyst) are rare benign cystic renal neoplasms that are composed of epithelial and stromal elements.
  • All cases had areas with increased stromal cellularity and 8 cases had ovarian-like stroma present at least focally within the tumor.
  • All cases have acted in a benign fashion with no history of recurrence or metastasis.
  • If the diagnosis of CN is limited to cases that are comprised entirely of thin fibrous-walled cysts, all 11 of our cases would be classified as MEST.
  • [MeSH-major] Kidney Diseases, Cystic / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Complex and Mixed / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Stromal Cells

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546041.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


61. Hakamada K, Miura T, Kimura A, Nara M, Toyoki Y, Narumi S, Sasak M: Anaplastic carcinoma associated with a mucinous cystic neoplasm of the pancreas during pregnancy: report of a case and a review of the literature. World J Gastroenterol; 2008 Jan 7;14(1):132-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma associated with a mucinous cystic neoplasm of the pancreas during pregnancy: report of a case and a review of the literature.
  • We herein report an unusual case of anaplastic carcinoma occurring with a recurrent mucinous cystic neoplasm in a 38-year-old female.
  • A 10-cm retroperitoneal cystic mass was pointed out in the first pregnancy and a probable diagnosis of mucinous cystic neoplasm was made in October 2000.
  • During her second pregnancy in 2002, however, she presented hematemesis and underwent urgent distal pancreatectomy, splenectomy and partial resection of the gastric wall where the tumor perforated.
  • A diagnosis of borderline-type mucinous cystic neoplasm with ovarian-like stroma was made.
  • Nine months later, CT visualized a recurrent cystic tumor near the pancreatic stump, which was subsequently resected.
  • Pathology revealed that the tumor was composed of two different components of borderline-type mucinous cystic neoplasm and anaplastic carcinoma.
  • She survived four years after the second surgery without tumor recurrence.
  • Although the origin of anaplastic carcinoma has not been determined yet, it should be remembered that anaplastic carcinoma can occur in association with mucinous cystic neoplasm of more benign histology.
  • [MeSH-major] Carcinoma / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] West J Med. 1982 Feb;136(2):157-62 [6278785.001]
  • [Cites] Cell. 1983 Aug;34(1):245-53 [6192933.001]
  • [Cites] Lab Invest. 1987 Oct;57(4):359-69 [3669613.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):494-8 [1702351.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2792-6 [1333354.001]
  • [Cites] Histopathology. 1995 Mar;26(3):284-7 [7541017.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Arch Pathol Lab Med. 1997 May;121(5):533-5 [9167613.001]
  • [Cites] AMA Arch Pathol. 1954 Aug;58(2):101-11 [13170907.001]
  • [Cites] Am J Clin Pathol. 1946 Mar;16:219-24 [21027097.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):86-91 [10658914.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):70-80 [8990143.001]
  • (PMID = 18176976.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 14
  • [Other-IDs] NLM/ PMC2673378
  •  go-up   go-down


62. Shen Y, Liang LZ, Hong MH, Xiong Y, Wei M, Zhu XF: [Expression and clinical significance of microtubule-associated protein 1 light chain 3 (LC3) and Beclin1 in epithelial ovarian cancer]. Ai Zheng; 2008 Jun;27(6):595-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of microtubule-associated protein 1 light chain 3 (LC3) and Beclin1 in epithelial ovarian cancer].
  • BACKGROUND & OBJECTIVE: Some studies have showed that changes of autophagic capacity may be correlated to tumorigenesis and tumor development.
  • This study was to investigate the expression of microtubule-associated protein 1 light chain 3 (LC3) and autophagy-related gene Beclin1 in ovarian tumor tissues, and explore their correlations to the tumorigenesis and development of epithelial ovarian carcinoma.
  • METHODS: Expressions of LC3 and Beclin1 in 25 specimens of benign ovarian tumor, 25 specimens of borderline ovarian tumor, and 75 specimens of epithelial ovarian carcinoma were detected by immunohistochemistry.
  • The correlations of LC3 and Beclin1 expression to the clinicopathologic characteristics of the 75 epithelial ovarian cancer patients were analyzed.
  • RESULTS: The positive rates of LC3 and Beclin1 were significantly higher in benign and borderline ovarian tumors than in epithelial ovarian carcinoma (100% and 96% vs. 57%, P<0.001; 100% and 84% vs. 57%, P<0.001).
  • CONCLUSIONS: Expressions of LC3 and Beclin1 are down-regulated in epithelial ovarian cancer tissues.
  • The decrease of autophagic capacity may relate to tumorigenesis and the development of epithelial ovarian cancer.
  • [MeSH-major] Apoptosis Regulatory Proteins / analysis. Membrane Proteins / analysis. Microtubule-Associated Proteins / analysis. Neoplasms, Glandular and Epithelial / chemistry. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Autophagy. Female. Humans. Immunohistochemistry. Middle Aged. Ovary / chemistry

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570732.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BECN1 protein, human; 0 / Membrane Proteins; 0 / Microtubule-Associated Proteins; 0 / light chain 3, human
  •  go-up   go-down


63. Malkan AD, Braich PS, Panait L, Dudrick SJ: Mucinous cystadenoma of the ovary presenting as unilateral lower extremity edema. Conn Med; 2009 Oct;73(9):517-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystadenoma of the ovary presenting as unilateral lower extremity edema.
  • INTRODUCTION: Mucinous cystadenomas of the ovary are known for their potential to grow to massive proportions and are often incidentally diagnosed.
  • They are typically benign tumors accounting for 15% of ovarian neoplasms and up to 80% of all mucinous tumors.
  • CASE REPORT: We report a 50-year-old, morbidly obese female admitted with left lower extremity edema who was incidentally found to have a massive, benign, mucinous cystadenoma of the ovary.
  • The tumor was managed by laparotomy, cystectomy, and right salpingo-oophorectomy.
  • Pathology revealed a benign cyst.
  • CONCLUSION: The clinically silent course of these large, benign tumors can have unique presentations.
  • [MeSH-major] Cystadenoma, Mucinous / diagnosis. Edema / etiology. Ovarian Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Conn Med. 2013 Aug;77(7):448. Singh-Braich, Puneet [corrected to Braich, Puneet Singh]
  • (PMID = 19860270.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. An HJ, Kim DS, Park YK, Kim SK, Choi YP, Kang S, Ding B, Cho NH: Comparative proteomics of ovarian epithelial tumors. J Proteome Res; 2006 May;5(5):1082-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomics of ovarian epithelial tumors.
  • We analyzed 12 ovarian epithelial tumors using 2D PAGE-based comparative proteomics to construct intra- and inter-tumoral distance map trees and to discover surrogate biomarkers indicative of an ovarian tumor.
  • The analysis was performed after laser microdissection of 12 fresh-frozen tissue samples, including 4 serous, 5 mucinous, and 3 endometrioid tumors, with correlation with their histopathological characteristics.
  • Ovarian epithelial tumors and normal tissues showed an apparent separation on the distance map tree.
  • All mucinous tumors with aggressive histology were separated from the low malignant potential (LMP) group.
  • The benign-looking cysts adjacent to the intraepithelial carcinoma (IEC) showed an expression pattern identical to that of the IEC area.
  • The potential candidate biomarkers screened in ovarian tumors and found to be significantly up-regulated in comparison to normal tissues were as follows: NM23, annexin-1, protein phosphatase-1, ferritin light chain, proteasome alpha-6, and NAGK (N-acetyl glucosamine kinase).
  • In conclusion, ovarian mucinous tumors are distinct from other ovarian epithelial tumors.
  • LMP mucinous tumors showing histologically aggressive features belong to mucinous carcinoma on the proteomic basis.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Proteomics / methods
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cluster Analysis. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Middle Aged. Models, Biological. Reference Values. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods


65. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS: Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control; 2008 Dec;19(10):1357-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery.
  • OBJECTIVE: Some forms of ovarian neoplasms may be preventable through the removal of precursor lesions.
  • We assessed the risk associated with a prior diagnosis of, and ovarian surgery following, ovarian cysts and endometriosis, with a focus on characterizing risk among tumor subgroups.
  • METHODS: Information was collected during in-person interviews with 812 women with ovarian cancer diagnosed in western Washington State from 2002 to 2005 and 1,313 population-based controls.
  • RESULTS: The risk of a borderline mucinous ovarian tumor associated with a history of an ovarian cyst was increased (OR=1.7, 95% CI: 1.0-2.8), but did not vary notably according to receipt of subsequent ovarian surgery.
  • While risk of invasive epithelial ovarian cancer was slightly increased among women with a cyst who had no subsequent ovarian surgery, it was reduced when a cyst diagnosis was followed by surgery (OR = 0.6, 95% CI: 0.4-0.9).
  • This reduction in risk was most evident for serous invasive tumors.
  • Women with a history of endometriosis had a threefold increased risk of endometrioid and clear cell invasive tumors, with a lesser risk increase among women who underwent subsequent ovarian surgery.
  • CONCLUSIONS: Our results suggest differences in the relation of ovarian cysts and endometriosis with risk of specific subtypes of ovarian cancer as well as the possibility that ovarian surgery in women with these conditions may lower the risk of invasive disease.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Epidemiol. 2000 Jan;10(1):14-23 [10658685.001]
  • [Cites] Cancer Causes Control. 2008 May;19(4):413-20 [18080774.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1060-3 [10744092.001]
  • [Cites] Eur J Cancer Prev. 2001 Apr;10(2):197-9 [11330466.001]
  • [Cites] Gynecol Oncol. 2001 Oct;83(1):100-8 [11585420.001]
  • [Cites] Am J Epidemiol. 2002 Feb 1;155(3):217-24 [11821246.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jul;189(1):280-94 [12861175.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Apr;83(4):395-400 [15005789.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):200-5 [15213595.001]
  • [Cites] Epidemiology. 1996 May;7(3):319-22 [8728451.001]
  • [Cites] Int J Epidemiol. 1997 Aug;26(4):710-5 [9279601.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1634-7 [9389926.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):299-305 [15734950.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):318-22 [15863124.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2929-35 [16365012.001]
  • [Cites] Hum Reprod. 2006 May;21(5):1237-42 [16431901.001]
  • [Cites] Cancer Causes Control. 2006 Jun;17(5):623-32 [16633908.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):37-43 [17291229.001]
  • [Cites] Clin Med Res. 2007 Mar;5(1):35-44 [17456833.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):223-30 [17662378.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2548-56 [18086757.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1028-9 [10744081.001]
  • (PMID = 18704718.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA087538-01A2; United States / NCI NIH HHS / CA / R01 CA087538-05; United States / NCI NIH HHS / CA / R01 CA087538; United States / NCI NIH HHS / CA / R01 CA87538; United States / NCI NIH HHS / CA / R01 CA087538-02; United States / NCI NIH HHS / CA / CA087538-05; United States / NCI NIH HHS / CA / R01 CA087538-03; United States / NCI NIH HHS / CA / R01 CA087538-04; United States / NCI NIH HHS / CA / CA087538-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS146032; NLM/ PMC2751585
  •  go-up   go-down


66. Naik R, Cross P, Lopes A, Godfrey K, Hatem MH: "True" versus "apparent" stage I epithelial ovarian cancer: value of frozen section analysis. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "True" versus "apparent" stage I epithelial ovarian cancer: value of frozen section analysis.
  • The aim of this prospective study was to determine the clinical benefits of introducing peroperative frozen section analysis into the surgical management policy of women referred with an adnexal mass suspicious of ovarian cancer.
  • Correlation was determined between cases surgically staged following the frozen section result and the clinical need for staging based on the pathologic diagnosis from the paraffin section.
  • Paraffin section diagnoses included 74 benign tumors, 11 borderline tumors, 34 primary epithelial cancers, 5 nonepithelial cancers, and 6 metastatic tumors.
  • All primary epithelial ovarian cancers were correctly identified as requiring a staging procedure based on the frozen section result.
  • Four of seventy-four cases reported as benign on frozen section analysis were underdiagnosed; two were later diagnosed on paraffin section as borderline tumors and a further two as malignant (one low-grade adenosarcoma and one primary peritoneal cancer).
  • Excluding the borderline tumors, metastatic tumors, and primary peritoneal tumor where staging did not impact subsequent clinical management, the statistical test results for frozen section analysis in determining the need for a staging procedure were sensitivity = 97%, specificity = 95%, positive predictive value = 90%, and negative predictive value = 99%.
  • The clinical benefits of introducing frozen section analysis in the surgical staging policy of women with an adnexal mass suspicious of ovarian malignancy included avoidance of a surgical staging procedure in 95% of cases identified on paraffin section analysis to be benign.
  • This benefit was without compromising the avoidance of chemotherapy in true stage I epithelial ovarian cancer cases.
  • [MeSH-major] Frozen Sections. Ovarian Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Intraoperative Period. Neoplasm Metastasis. Neoplasm Staging. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515566.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Iavazzo C, Vorgias G, Sampanis D, Mavromatis I, Manikis P, Katsoulis M: Meig's or Pseudomeig's syndrome? Bratisl Lek Listy; 2007;108(3):158-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The triad of ascites, hydrothorax in association with a benign ovarian tumor is defined as Meig's syndrome.
  • [MeSH-major] Meigs Syndrome / diagnosis
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Female. Humans. Middle Aged. Ovarian Neoplasms / complications. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682545.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


68. Ouellet V, Ling TH, Normandin K, Madore J, Lussier C, Barrès V, Bachvarov D, Rancourt C, Tonin PN, Provencher DM, Mes-Masson AM: Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. BMC Cancer; 2008;8:346
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.
  • BACKGROUND: Serous epithelial ovarian tumors can be subdivided into benign (BOV), low malignant potential (LMP) or borderline and invasive (TOV) tumors.
  • Although the molecular characteristics of serous BOV, LMP and low grade (LG) TOV tumors has been initiated, definitive immunohistochemical markers to distinguish between these tumor types have not been defined.
  • METHODS: In the present study, we used a tissue array composed of 27 BOVs, 78 LMPs and 23 LG TOVs to evaluate the protein expression of a subset of selected candidates identified in our previous studies (Ape1, Set, Ran, Ccne1 and Trail) or known to be implicated in epithelial ovarian cancer disease (p21, Ccnb1, Ckd1).
  • RESULTS: Statistically significant difference in protein expression was observed for Ccnb1 when BOV tumors were compared to LMP tumors (p = 0.003).
  • When BOV were compared to LG TOV tumors, Trail was significantly expressed at a higher level in malignant tumors (p = 0.01).
  • Expression of p21 was significantly lower in LG tumors when compared with either BOVs (p = 0.03) or LMPs (p = 0.001).
  • We also observed that expression of p21 was higher in LMP tumors with no (p = 0.02) or non-invasive (p = 0.01) implants compared to the LMP associated with invasive implants.
  • CONCLUSION: This study represents an extensive analyse of the benign and highly differentiated ovarian disease from an immunohistochemical perspective.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):175-81 [18317226.001]
  • [Cites] Virchows Arch. 2000 Mar;436(3):224-8 [10782880.001]
  • [Cites] Pathol Biol (Paris). 2000 Apr;48(3):190-202 [10858953.001]
  • [Cites] Hum Pathol. 2000 Jun;31(6):698-704 [10872663.001]
  • [Cites] Virchows Arch. 2000 May;436(5):403-12 [10881733.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3131-8 [10955794.001]
  • [Cites] Hum Pathol. 2000 Dec;31(12):1506-14 [11150376.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1B):521-8 [11299798.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Oncogene. 2002 Aug 22;21(37):5804-13 [12173052.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1111-28 [12218568.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3865-71 [12228206.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2002 Aug;16(4):499-512 [12413931.001]
  • [Cites] Cancer. 2003 May 15;97(10 Suppl):2631-42 [12733128.001]
  • [Cites] Histol Histopathol. 2003 Jul;18(3):761-70 [12792888.001]
  • [Cites] J Pathol. 2003 Jul;200(3):327-35 [12845629.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1078-85 [12853350.001]
  • [Cites] Virchows Arch. 2003 Jul;443(1):38-43 [12756564.001]
  • [Cites] Gut. 2004 Feb;53(2):235-40 [14724156.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:135-66 [14763172.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Mar;149(2):98-106 [15036884.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14 [15184677.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):918-33 [15297960.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):934-48 [15297961.001]
  • [Cites] Bull Cancer. 1982;69(3):228-38 [6289947.001]
  • [Cites] Mod Pathol. 1988 Nov;1(6):407-14 [2464824.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):397-403 [2318481.001]
  • [Cites] Hematol Oncol Clin North Am. 1992 Aug;6(4):739-60 [1500384.001]
  • [Cites] Hematol Oncol Clin North Am. 1992 Aug;6(4):761-82 [1500385.001]
  • [Cites] Int J Gynecol Pathol. 1993 Jan;12(1):20-7 [7678103.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):701-4 [8259214.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):521-7 [8666359.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):278-86 [8674004.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1319-30 [8898836.001]
  • [Cites] Biochem Biophys Res Commun. 1997 May 19;234(2):300-2 [9177263.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):397-409 [10199469.001]
  • [Cites] Mol Cancer. 2004 Oct 7;3:27 [15471544.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1053-65 [15558012.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S33-50 [15761465.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):453-61 [15882169.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):707-23 [15897738.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4672-87 [15940270.001]
  • [Cites] Oncol Rep. 2005 Aug;14(2):363-8 [16012716.001]
  • [Cites] Histopathology. 2005 Sep;47(3):310-5 [16115232.001]
  • [Cites] Oncol Rep. 2005 Oct;14(4):837-46 [16142340.001]
  • [Cites] Semin Oncol. 2005 Oct;32(5):452-7 [16210085.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7273-9 [16243797.001]
  • [Cites] Histol Histopathol. 2006 Jan;21(1):81-92 [16267789.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):599-607 [16572426.001]
  • [Cites] Clin Obstet Gynecol. 2006 Sep;49(3):517-25 [16885658.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2119-26 [16823850.001]
  • [Cites] J Pathol. 2006 Oct;210(2):147-54 [16850502.001]
  • [Cites] J Cell Physiol. 2007 Jan;210(1):183-91 [16998811.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2007 Feb;13(1):9-14 [17392664.001]
  • [Cites] Exp Oncol. 2007 Mar;29(1):49-53 [17431389.001]
  • [Cites] Clin Med Res. 2007 Mar;5(1):35-44 [17456833.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):297-308 [17569106.001]
  • (PMID = 19032793.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2610034
  •  go-up   go-down


69. Szymanska-Pasternak J, Szymanska A, Medrek K, Imyanitov EN, Cybulski C, Gorski B, Magnowski P, Dziuba I, Gugala K, Debniak B, Gozdz S, Sokolenko AP, Krylova NY, Lobeiko OS, Narod SA, Lubinski J: CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol; 2006 Sep;102(3):429-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors.
  • METHODS: To establish if these variants play a role in the etiology of ovarian tumors, we genotyped 1108 Polish women with various types of ovarian tumors and 4000 controls for the three CHEK2 variants.
  • We included 539 Polish women with benign ovarian cystadenomas, 122 women with borderline ovarian malignancies and 447 women with invasive ovarian cancer.
  • RESULTS: Positive associations were seen with the CHEK2 I157T missense variant and ovarian cystadenomas (OR = 1.7; P = 0.005), with borderline ovarian cancers (OR = 2.6; P = 0.002) and with low-grade invasive cancers (OR = 2.1; P = 0.04).
  • There was no association with ovarian cancer of high grade (OR = 1.0).
  • The association between the I157T missense variant was then confirmed in a second sample of Russian patients with borderline ovarian cancers (OR = 2.7; P = 0.06).
  • CONCLUSION: These data indicate that CHEK2 variants may predispose to a range of ovarian tumor types of low malignant potential, but not to aggressive cancers.
  • [MeSH-major] Genetic Predisposition to Disease. Mutation, Missense. Ovarian Neoplasms / genetics. Protein-Serine-Threonine Kinases / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16828850.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


70. Zhang PJ, Gao HG, Pasha TL, Litzky L, Livolsi VA: TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int J Gynecol Pathol; 2009 Jan;28(1):10-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems.
  • We evaluated TTF-1 expression with 3 primary different antibodies (8G7G3/1, SPT24, and BGX-397A) and 2 secondary automated detection systems (Envision+/Dako autostainer versus Refine/Bond Max) in 104 ovarian and endometrial tumors on routine surgical specimens and 108 ovarian tumors on tissue microarray (TMA) specimens.
  • By using SPT24/Refine/Bond Max, TTF-1 reactivity could be detected in all major histologic subtypes of gynecologic tumors and up to 26% of all cases tested on routine surgical specimens and 6.4% on TMA.
  • TTF-1 was most frequently detected in uterine malignant mixed Müllerian tumor (82%), more common in uterine tumors than ovarian tumors, and more common in surgical specimen than TMA.
  • When present, tumor cells can be rarely positive or diffusely positive for TTF-1 reactivity.
  • In addition to malignant tumors, TTF-1 was also detected in benign tumors and benign tubal and endometrial epithelia.
  • TTF 1 immunostaining has the potential to misguide a pathologist to conclude an ovarian or endometrial tumor being a lung metastasis.
  • However, the role of TTF-1 in female genital tract and its tumors is unknown.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Neoplasms / metabolism. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047914.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


71. Zhang S, Zhou X, Yu H, Yu Y: Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer; 2010;10:163
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines.
  • BACKGROUND: To observe mRNA expression of tumor-specific antigen MAGE, BAGE and GAGE in epithelial ovarian cancer tissues and cell lines, to explore the relationship between gene expression and diagnosis, treatment and prognosis of ovarian cancer, and to evaluate the feasibility of their gene products as markers, and an immunotherapy target for ovarian cancer.
  • METHODS: mRNA expression of MAGE-1, MAGE-3, GAGE-1/2 and BAGE were determined by reverse transcription polymerase chain reaction (RT-PCR) in 14 cases of normal ovarian tissue, 20 cases of ovarian benign tumor specimens, 41 cases of ovarian cancer specimens, and ovarian cancer cell lines SKOV3, A2780, and COC1.
  • RESULTS: MAGE, GAGE and BAGE genes were not expressed in normal ovarian tissue.
  • In benign tumors, only the MAGE gene was expressed; the expression rate of this gene in benign tumors was 15% (3/20).
  • In ovarian cancer tissues, MAGE-1 and MAGE-3 was highly expressed, with expression rates of 53.7% (22/41) and 36.6% (15/41), while GAGE-1/2 and BAGE had relatively low expression, with rates of 26.8% (11/41) and 14.6% (6/41).
  • In metastatic lesions of ovarian cancer, only MAGE-1 and BAGE were expressed, with expression rates of 28.6% (2/7) and 14.3% (1/7).
  • The positive expression rates of MAGE-1 and MAGE-3 in serous cystadenocarcinoma were significantly higher than that in other types of ovarian cancer (P < 0.05).
  • Positive expression of MAGE-1 and MAGE-3 was positively correlated with tumor differentiation and the clinical stage of the ovarian cancer.
  • In addition, the positive expression rate of BAGE was significantly higher in ovarian cancer patients with ascites (P < 0.05).
  • The mRNA expression profiles of MAGE, GAGE and BAGE in ovarian carcinoma cell lines SKOV3, A2780 and COC1 varied, but there was at least one gene expressed in each cell line.
  • CONCLUSION: Tumor-specific antigen MAGE, BAGE and GAGE may play a role in the occurrence and development of ovarian cancer.
  • These genes can be used as one of the important indicators for early diagnosis, efficacy evaluation and prognostic determination of ovarian cancer.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Cystadenocarcinoma, Serous / genetics. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Feasibility Studies. Female. Gene Expression Regulation, Neoplastic. Humans. Melanoma-Specific Antigens. Neoplasm Staging. Prognosis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tissue Antigens. 2000 Aug;56(2):166-9 [11019919.001]
  • [Cites] Cancer. 2002 Jun 25;96(3):187-93 [12115308.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):1051-73 [12959191.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):457-60 [8707425.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3931-40 [18483279.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):9008-21 [16061912.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1650-5 [18216244.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):3585-93 [18292586.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):816-21 [9743307.001]
  • (PMID = 20423514.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / BAGE protein, human; 0 / Biomarkers, Tumor; 0 / GAGE1 protein, human; 0 / GAGE2A protein, human; 0 / MAGEA1 protein, human; 0 / MAGEA3 protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2868811
  •  go-up   go-down


72. Kauppila S, Altinörs M, Väre P, Liakka A, Knuuti E, Nissi R: Primary sex cord-like variant of endometrioid adenocarcinoma arising from endometriosis. APMIS; 2008 Sep;116(9):842-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although endometriosis is a benign disease, some malignant tumors have been reported to develop in endometriotic lesions, most commonly in the ovary.
  • The relationship between endometriosis and malignancy is not well known, but the majority of endometriosis-associated ovarian malignancies are usually endometrioid adenocarcinomas and clear cell carcinomas.
  • The sex cord-like variant of endometrioid adenocarcinoma is a rare tumor that histologically closely resembles the sex cord-stromal tumor.
  • Despite its rarity, the correct histological diagnosis of the sex cord-like variant of endometrioid adenocarcinoma is crucial to avoid misdiagnosis of a less aggressive tumor.
  • The tumor was diagnosed based on light microscopy and immunohistochemistry.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024607.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


73. Swierzko AS, Florczak K, Cedzyński M, Szemraj J, Wydra D, Bak-Romaniszyn L, Emerich J, Sułowska Z: Mannan-binding lectin (MBL) in women with tumours of the reproductive system. Cancer Immunol Immunother; 2007 Jul;56(7):959-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated mbl2 genotypes, MBL concentrations, and MBL-MASP-2 complex activity in patients with ovarian cancer.
  • The expression of both mbl2 and masp-2 genes were investigated in ovarian tissue sections.
  • Additionally, samples from patients with other malignant and benign tumours of the reproductive tract were tested.
  • MBL-specific mRNA expression was detected in several normal and malignant ovarian tissues, as well as in ovarian epithelial cell lines.
  • Intracellular staining with MBL-specific antibodies demonstrated the presence of MBL in ovarian cell lines, and in normal as well as malignant ovarian tissue sections.
  • In contrast, MASP-2-specific mRNA expression was detected only in the ovary tissues of patients with malignant disease.
  • MBL was detected in ascites and in the fluid of benign ovarian cysts.
  • However, it cannot be excluded that mbl-2 mutant alleles may be in linkage disequilibrium with an unidentified tumour susceptibility gene(s).
  • [MeSH-major] Mannose-Binding Lectin / metabolism. Ovarian Neoplasms / genetics. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Flow Cytometry. Gene Expression. Gene Expression Profiling. Genotype. Haplotypes. Humans. Immunohistochemistry. Mannose-Binding Protein-Associated Serine Proteases / analysis. Mannose-Binding Protein-Associated Serine Proteases / metabolism. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131120.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mannose-Binding Lectin; EC 3.4.21.- / MASP2 protein, human; EC 3.4.21.- / Mannose-Binding Protein-Associated Serine Proteases
  •  go-up   go-down


74. Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R, Godwin AK, Newman R, Mills G: Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol; 2007;433:1-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis.
  • Thus, ideal conditions are established to increase lysophospholipids in the tumor microenvironment.
  • Indeed, ascites from ovarian cancer patients, which reflects both the tumor environment and a tumor-conditioned media, exhibits markedly elevated levels of specific lysophospholipids as well as one of the enzymes involved in production of lysophospholipids: autotaxin (ATX).
  • The potential sources of lysophospholipids in the tumor microenvironment include tumor cells and stroma, such as mesothelial cells, as well as inflammatory cells and platelets activated by the proinflammatory tumor environment.
  • If lysophospholipids diffuse from the tumor microenvironment into the bloodstream and persist, they have the potential to serve as early diagnostic markers as well as potential monitors of tumor response to therapy.
  • Many scientific and technical challenges need to be resolved to determine whether lysophospholipids or the enzymes producing lysophospholipids alone or in combination with other markers have the potential to contribute to early diagnosis.
  • Using liquid chromatography mass spectrometry (LC/MS/MS), we quantified the amount of lysophosphatidic acid (16:0, 18:0, 18:1, 18:2, and 20:4), lysophosphatidylinositol (18:0), lysophosphatidylserine (18:1), lysophosphatidylcholine (16:0, 18:0, 18:1, 18:2, and 20:4), sphingosine-1-phosphate, and sphingosylphosphorylcholine species from human female plasma samples with malignant, benign, or no breast tumor present.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Lysophospholipids / blood

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954226.001).
  • [ISSN] 0076-6879
  • [Journal-full-title] Methods in enzymology
  • [ISO-abbreviation] Meth. Enzymol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 1 T90 070109-01; United States / NCI NIH HHS / CA / P01 CA64602; United States / NCI NIH HHS / CA / P50 CA083639
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lysophospholipids
  •  go-up   go-down


75. Ye L, Wu XL, Xu L, Huang Q, Sun L, He Y, Yang KX: [Ovarian steroid cell tumor, not otherwise specified: a clinicopathologic study]. Zhonghua Bing Li Xue Za Zhi; 2007 Aug;36(8):516-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian steroid cell tumor, not otherwise specified: a clinicopathologic study].
  • OBJECTIVE: To study the clinicopathologic features, diagnostic criteria, differential diagnosis and treatment options of ovarian steroid cell tumor, not otherwise specified (NOS).
  • METHODS: Light microscopy and immunohistochemical study was carried out in 8 cases of ovarian steroid cell tumor, NOS.
  • RESULTS: The 7 cases of benign ovarian steroid cell tumor, NOS were composed mainly of polygonal cells with granular eosinophilic cytoplasm and larger cells with vacuolated cytoplasm.
  • The single case of malignant ovarian steroid cell tumor had evidence of significant cellular pleomorphism, haemorrhage and coagulative tumor necrosis.
  • Immunohistochemical study showed that the tumor cells expressed calretinin and alpha-inhibin.
  • Differential diagnosis included oxyphilic granulosa cell tumor, thecoma, Sertoli cell tumor and clear cell carcinoma.
  • The treatment options of benign ovarian steroid cell tumor, NOS was local excision or ipsilateral salpingo-oophorectomy, while the malignant counterpart should be treated with a combination of surgery and chemotherapy, including administration of GnRH agonist.
  • CONCLUSIONS: Ovarian steroid cell tumor, NOS, is the most common type of ovarian steroid cell tumors.
  • Most of which are associated with a benign clinical outcome.
  • Immunohistochemistry is an important adjunct for diagnosis.
  • The treatment options of ovarian steroid cell tumor, NOS depend on its malignant potential.
  • [MeSH-major] Inhibins / metabolism. Ovarian Neoplasms / pathology. Ovary / pathology. S100 Calcium Binding Protein G / metabolism. Sex Cord-Gonadal Stromal Tumors / pathology
  • [MeSH-minor] Adolescent. Adult. Calbindin 2. Diagnosis, Differential. Female. Granulosa Cell Tumor / pathology. Humans. Ovariectomy / methods. Sertoli Cell Tumor / pathology. Thecoma / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980097.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins
  • [Number-of-references] 27
  •  go-up   go-down


76. Kanehara H, Bando Y, Tomita M, Kontani M, Takegoshi Y, Tanaka N: Myxedema ascites with an extremely elevated CA125 Level: a case report. Endocr J; 2007 Aug;54(4):601-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carbohydrate antigen 125 (CA125) is a tumor-marker frequently associated with ovarian malignancies; however, benign gynecologic conditions (e.g. ovarian cysts) commonly cause a smaller increase in CA125 levels.
  • Her serum CA125 level was markedly elevated (822 U/ml) and abdominal CT revealed a right ovarian cyst and massive ascites.
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Female. Humans. Thyroxine / therapeutic use

  • Genetic Alliance. consumer health - Myxedema.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641444.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


77. Kaji M, Kabir-Salmani M, Anzai N, Jin CJ, Akimoto Y, Horita A, Sakamoto A, Kanai Y, Sakurai H, Iwashita M: Properties of L-type amino acid transporter 1 in epidermal ovarian cancer. Int J Gynecol Cancer; 2010 Apr;20(3):329-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Properties of L-type amino acid transporter 1 in epidermal ovarian cancer.
  • HYPOTHESIS: To investigate the expression and the functional properties of L-type amino acid transporter 1 (LAT1) in human epithelial ovarian cancer to provide a basis for potential new therapies to control the growth and the metastasis of ovarian cancer.
  • The expression of LAT1 in 53 cases of ovarian cancers was determined by Western blot and immunohistochemical staining, and results were compared with those of normal ovarian tissues (5 cases) and benign ovarian tumors (5 cases).
  • Furthermore, we examined the effect of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), the classic inhibitor of system L on the survival, the migration, and the uptake of l-leucine by human epithelial ovarian cancer cell line (OVCAR-3).
  • RESULTS: The LAT1 was significantly up-regulated in various human epithelial ovarian cancers that was localized predominantly on their plasma membrane and in the plasma membrane of the ovarian cancer cell line in conjunction with 4F2hc via disulfide bonds.
  • CONCLUSIONS: The LAT1 plays significant roles in nutrition, proliferation, and migration of ovarian cancer.
  • Then, LAT1 inhibition would be useful for anticancer therapy in suppressing tumor growth without affecting normal tissues.
  • [MeSH-major] Large Neutral Amino Acid-Transporter 1 / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Amino Acids, Cyclic / pharmacology. Blotting, Western. Cell Adhesion / drug effects. Cell Movement / drug effects. Cell Proliferation / drug effects. Female. Fluorescent Antibody Technique. Humans. Immunoenzyme Techniques. Leucine / metabolism. Ovary / drug effects. Ovary / metabolism. Ovary / pathology. Peptide Fragments / immunology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. L-Leucine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375792.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids, Cyclic; 0 / Large Neutral Amino Acid-Transporter 1; 0 / Peptide Fragments; 20448-79-7 / 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid; GMW67QNF9C / Leucine
  •  go-up   go-down


78. Dai SY, Hata K, Inubashiri E, Kanenishi K, Shiota A, Ohno M, Yamamoto Y, Nishiyama Y, Ohkawa M, Hata T: Does three-dimensional power Doppler ultrasound improve the diagnostic accuracy for the prediction of adnexal malignancy? J Obstet Gynaecol Res; 2008 Jun;34(3):364-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of the present study was to investigate the diagnostic accuracy of three-dimensional power Doppler ultrasound (3DPD) in the differentiation between benign and malignant adnexal masses and evaluate 3DPD for assessing malignancy in comparison with two-dimensional transvaginal gray-scale sonography (2DTVS), magnetic resonance imaging (MRI) and positron emission tomography (PET).
  • Final diagnosis was confirmed by the postoperative histopathology.
  • RESULTS: Of the 36 patients, 25 had a malignancy, 5 had a borderline tumor, and 6 had a benign mass.
  • [MeSH-major] Adnexal Diseases / diagnosis. Genital Neoplasms, Female / diagnosis. Ultrasonography, Doppler / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Fallopian Tube Neoplasms / diagnosis. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18686352.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


79. McCluggage WG: Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol; 2010 Mar;17(2):122-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mullerian adenosarcoma is an uncommon, but not rare, mixed tumor containing a neoplastic but benign or mildly atypical epithelial element and a sarcomatous, usually low-grade, stromal component.
  • The most common site is the uterine corpus but adenosarcoma also occurs in the cervix and ovary and more rarely in the vagina, fallopian tube, arising from peritoneal surfaces, or outside the female genital tract, for example in the intestine.
  • Characteristic histologic features include a low power "phyllodes-like" architecture with leaf-like projections lined by a variety of benign Mullerian type epithelia, sometimes with squamous metaplasia.
  • Using the World Health Organization definition, stromal mitotic activity of 2 or more per 10 high-power fields is required for a diagnosis of adenosarcoma but in practice the diagnosis is made with stromal mitotic activity less than this if the characteristic architecture and cambium layer is present.
  • Uterine adenosarcomas are, in general, low-grade neoplasms capable of local recurrence after polypectomy or hysterectomy and much less commonly distant metastasis.
  • Adenosarcoma may be confused with a variety of lesions and one of the main differential diagnoses is adenofibroma in which the stromal component is, by definition, morphologically benign.
  • Ovarian adenosarcomas are much more likely to exhibit malignant behavior than their uterine counterparts, probably due to the lack of an anatomic barrier to peritoneal dissemination.
  • [MeSH-major] Adenosarcoma / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenofibroma / pathology. Aged. Aged, 80 and over. Female. Humans. Ovarian Neoplasms / pathology. Postmenopause. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20179434.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


80. Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M, Douchi T: Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res; 2006 Jun;32(3):309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
  • AIM: New biomarkers other than carbohydrate antigen (CA) 125 are needed for the detection of ovarian cancer.
  • We evaluated the preoperative plasma OPN level as a diagnostic biomarker for ovarian cancer in comparison with CA125.
  • METHODS: Preoperative plasma OPN and CA125 levels were measured and compared in 32 patients with ovarian cancer, 34 patients with benign ovarian tumor, 30 patients with other gynecologic cancers and 31 healthy women.
  • Preoperative plasma OPN levels were also assessed according to tumor stage, the volume of ascites and histological types.
  • The sensitivity and specificity for predicting ovarian cancer was compared between OPN and CA125.
  • RESULTS: Preoperative plasma OPN levels were significantly higher in patients with ovarian cancer than in those with benign ovarian tumor, in other gynecologic patients or in healthy women.
  • Stage IV ovarian cancer patients and ovarian cancer patients with ascites had higher plasma OPN levels than those without ascites and in a lower stage.
  • The sensitivity of preoperative plasma OPN in detecting ovarian cancer was 81.3% and almost reached that of CA125.
  • CONCLUSION: Preoperative OPN is a useful biomarker for predicting ovarian cancer.
  • Larger studies of patients with ovarian cancer showing a low CA125 level or in early stages of ovarian cancer are needed.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Ovarian Neoplasms / blood. Sialoglycoproteins / blood

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764622.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


81. Gonzalez Bosquet E: [Elevated Ca 19.9 tumor marker without evidence of malignancy]. Medicina (B Aires); 2007;67(3):285-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Elevated Ca 19.9 tumor marker without evidence of malignancy].
  • [Transliterated title] Marcador tumoral Ca 19.9 aumentado sin evidencia de malignidad.
  • Tumor markers are a useful tool for surveillance of oncologic patients, whereas their role in the diagnosis of a malignancy is controversial.
  • We present the case of a woman with a benign ovarian cyst with an unexpected elevation of Ca 19.9 after laparoscopic bilateral anexectomy.
  • [MeSH-major] CA-19-9 Antigen / blood. Cystadenocarcinoma, Mucinous / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Cysts / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Laparoscopy. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17628919.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


82. Zhou JW, Gan NY, Zhang WJ: [The expression of MKP-1 and p-ERK(1/2) in primary ovarian epithelial tumor tissues]. Fen Zi Xi Bao Sheng Wu Xue Bao; 2009 Jun;42(3-4):224-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of MKP-1 and p-ERK(1/2) in primary ovarian epithelial tumor tissues].
  • To investigate the expression of mitogen activated protein kinase phosphatase-1 (MKP-1) and phosphorylation extracellular signal-regulated kinases (p-ERK(1/2)) in primary ovarian epithelial tumor tissues, and provide experiment's foundation on the new treatment in ovarian cancer.
  • Expression of MKP-1 and p-ERK(1/2) in tissues from 64 patients with primary ovarian epithelial tumor, 35 patients with ovarian epithelial bordline tumor, 32 patients with ovarian epithelial benign tumor and 26 normal ovarian tissues was detected by immunohistochemistry.
  • Immunohistochemistry and Western-blot assay showed that the expression of MKP-1 was gradually decreased in normal ovarian tissues, benign tumor, bordline tumor and carcinoma respectively, and there were significant differences among them (P < 0.01).
  • However, the expression of p-ERK(1/2) was gradually increased in normal ovarian tissues, benign tumor, bordline tumor and carcinoma respectively, and there were also significant differences among them (P < 0.01), the p-ERK(1/2) expression level in the carcinoma tissues of stage III/IV patients was significantly higher than that of stage I/II patients.
  • Expression of MKP-1 and p-ERK(1/2) in same ovarian carcinoma tissues detected by immunohistochemistry and Western-blot assay showed significant negative correlation (r = -0.90, P < 0.01 and r = -0.78, P < 0.01 respectively).
  • The expression changes of MKP-1 and ERKs may play a role in the development of ovarian carcinoma.
  • The abnormal expression of MKP-1 and p-ERK(1/2) probably assists in promoting the development and progression of ovarian carcinoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697705.001).
  • [ISSN] 1673-520X
  • [Journal-full-title] Fen zi xi bao sheng wu xue bao = Journal of molecular cell biology
  • [ISO-abbreviation] Fen Zi Xi Bao Sheng Wu Xue Bao
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.1.3.48 / Dual Specificity Phosphatase 1
  •  go-up   go-down


83. Stanwell P, Russell P, Carter J, Pather S, Heintze S, Mountford C: Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla. Invest Radiol; 2008 Oct;43(10):745-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla.
  • AIM: The purpose of this study was to determine the feasibility of acquiring in vivo proton magnetic resonance spectroscopy of ovarian lesions at a magnetic field strength of 3 Tesla (T).
  • The goal was to provide potentially diagnostic biochemical information that may aid in the characterization of ovarian neoplasms detected during clinical magnetic resonance imaging scanning.
  • Magnetic resonance spectral findings were correlated with the detailed pathology reports obtained after resection of each tumor.
  • RESULTS: Pathology revealed 7 patients with malignant surface epithelial-stromal tumors, 3 patients with germ cell tumors, 3 patients with benign serous cystadenomas, and 1 patient with a non-neoplastic endometrioma.
  • Resonances attributable to choline-containing compounds and Cr were recorded in all malignant tumors and some of the benign tumors.
  • When detected, a choline/Cr integral ratio of greater than 3 was found to indicate that a tumor was malignant in nature, whereas a choline/Cr integral ratio less than 1.5 was found to indicate that a tumor was benign in nature.
  • CONCLUSIONS: Spectroscopy of ovarian masses can be recorded at 3.0 T with acceptable spectral quality and good signal-to-noise ratio.
  • Further experience with a larger and more biologically variable range of tumors needs to be undertaken to determine the final clinical utility of this technique, but initial results from this small cohort are promising.
  • [MeSH-major] Magnetic Resonance Imaging / instrumentation. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791417.001).
  • [ISSN] 1536-0210
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Fine JL, Kagemann L, Wollstein G, Ishikawa H, Schuman JS: Direct scanning of pathology specimens using spectral domain optical coherence tomography: a pilot study. Ophthalmic Surg Lasers Imaging; 2010 Nov-Dec;41 Suppl:S58-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subtle textures that were suggestive of benign breast lobules and ovarian tumor features were also visible.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010, SLACK Incorporated.
  • [Cites] J Biomed Opt. 2002 Jul;7(3):457-63 [12175297.001]
  • [Cites] Arch Ophthalmol. 2003 May;121(5):695-706 [12742848.001]
  • [Cites] Hum Pathol. 2009 Aug;40(8):1057-69 [19552937.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Aug;66(8):750-9 [17882019.001]
  • [Cites] Hum Pathol. 2008 Apr;39(4):564-72 [18234276.001]
  • [Cites] Ophthalmology. 2005 Oct;112(10):1734-46 [16140383.001]
  • (PMID = 21117602.001).
  • [ISSN] 1938-2375
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / P30 EY008098; United States / NEI NIH HHS / EY / R01 EY013178; United States / NEI NIH HHS / EY / P30-EY08098; United States / NEI NIH HHS / EY / R01-EY13178
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS307169; NLM/ PMC3147151
  •  go-up   go-down


85. Artini PG, Ruggiero M, Monteleone P, Carpi A, Cristello F, Cela V, Genazzani AR: Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. Biomed Pharmacother; 2008 Jul-Aug;62(6):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
  • An imbalance between pro-angiogenic and anti-angiogenic factors is hypothesized in the pathogenesis of ovarian cystic disease.
  • The aim of the following study was to explore the possible role of free vascular endothelial growth factor receptor 1 (sVEGFR-1), a soluble regulator of vascular endothelial growth factor (VEGF) action, in ovarian cystoadenoma, endometriomata and cystoadenocarcinoma.
  • Forty-eight women, of whom fourteen had ovarian serous cysts, twenty-eight had stage III-IV ovarian endometriomata, and six had stage IIIB-IIIC ovarian carcinoma, were included.
  • Sampling of serum, peritoneal and ovarian cystic fluids and of tumor tissue was performed before, during and following surgery, respectively.
  • VEGF and sVEGFR-1 expression was evaluated in tumor tissue.
  • Western blot evidenced a marked expression of VEGF and soluble VEGFR-1 in endometriosis tissue with respect to benign cyst tissue but a lower expression of both molecules, contrary to that expected, in cancer tissue.
  • In conclusion, all in all, our data indicate that an excess of local VEGF with respect to its soluble receptor VEGFR-1 may be a key factor in the onset and maintenance of pathological neo-angiogenesis in ovarian cyst formation.
  • [MeSH-major] Ovarian Diseases / metabolism. Ovarian Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism
  • [MeSH-minor] Adult. Aged. Ascitic Fluid / chemistry. Cyst Fluid / chemistry. Cystadenocarcinoma / metabolism. Cystadenoma / metabolism. Endometriosis / metabolism. Female. Gene Expression. Humans. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / physiopathology. Ovarian Cysts / metabolism. Ovarian Cysts / physiopathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18037256.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


86. Zhao Y, Zong ZH, Xu HM: RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9. Gynecol Oncol; 2010 Mar;116(3):563-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.
  • OBJECTIVE: To determine the clinicopathological significance of RhoC expression in human ovarian cancer and its effect on the expression of vascular endothelial growth factor (VEGF), Rho-associated coiled-coil-forming kinase (ROCK), and metal matrix proteinases (MMPs).
  • METHODS: Tissue samples from normal ovaries, benign ovarian tumors, and epithelial ovarian cancer were collected.
  • Small interfering RNA (siRNA) was also used to target RhoC expression in the OVCAR3 and CaOV3 ovarian cancer cell lines, after which cell invasion and migration assays were performed, and the expression of ROCK-I, VEGF, and MMP9 was evaluated.
  • RESULTS: The expression levels of RhoC, ROCK-I, VEGF, and MMP9 mRNA and protein were significantly higher in ovarian cancer, showing a correlation with clinical stage but not histological type.
  • CONCLUSION: The expression level of RhoC is correlated to clinical stage and vascularization in ovarian cancer.
  • [MeSH-major] Matrix Metalloproteinase 9 / biosynthesis. Ovarian Neoplasms / metabolism. Vascular Endothelial Growth Factor A / biosynthesis. rho GTP-Binding Proteins / biosynthesis. rho-Associated Kinases / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cell Movement / physiology. Female. Humans. Matrix Metalloproteinase Inhibitors. Middle Aged. Neoplasm Invasiveness. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Small Interfering / administration & dosage. RNA, Small Interfering / genetics. Transfection. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20022093.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 0 / RHOC protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / rho-Associated Kinases; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


87. Wang C, Zhou L, Li S, Wei J, Wang W, Zhou T, Liao S, Weng D, Deng D, Weng Y, Wang S, Ma D: C4orf7 contributes to ovarian cancer metastasis by promoting cancer cell migration and invasion. Oncol Rep; 2010 Oct;24(4):933-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C4orf7 contributes to ovarian cancer metastasis by promoting cancer cell migration and invasion.
  • In this study, we report the expression of gene C4orf7 in a panel of tumor types.
  • The percentages of C4orf7 positive expression in the tumor patients with metastases were notably higher than those in the cancer without metastases.
  • On the contrary, the expression was hardly noted in normal tissues and corresponding benign lesions.
  • In vitro, the up-regulation of C4orf7 in ovarian cancer cell lines was associated with enhanced motility and invasiveness.
  • The role of C4orf7 in ovarian cancer cell morphology, motility and invasion was demonstrated.
  • [MeSH-major] Neoplasm Invasiveness / genetics. Ovarian Neoplasms / pathology. Proteins / metabolism
  • [MeSH-minor] Blotting, Western. Cell Movement / genetics. Female. Gene Expression. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction


88. Tinelli A, Vergara D, Martignago R, Leo G, Pisanò M, Malvasi A: An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Curr Genomics; 2009 Jun;10(4):240-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings.
  • Among the gynaecological malignancies, ovarian cancer is one of the neoplastic forms with the poorest prognosis and with the bad overall and disease-free survival rates than other gynaecological cancers.
  • Ovarian tumors can be classified on the basis of the cells of origin in epithelial, stromal and germ cell tumors.
  • Epithelial ovarian tumors display great histological heterogeneity and can be further subdivided into benign, intermediate or borderline, and invasive tumors.
  • Several studies on ovarian tumors, have focused on the identification of both diagnostic and prognostic markers for applications in clinical practice.
  • High-throughput technologies have accelerated the process of biomolecular study and genomic discovery; unfortunately, validity of these should be still demonstrated by extensive researches on sensibility and sensitivity of ovarian cancer novel biomarkers, determining whether gene profiling and proteomics could help differentiate between patients with metastatic ovarian cancer and primary ovarian carcinomas, and their potential impact on management.
  • In this review, the current state of knowledge about the genoproteomic and potential clinical value of gene expression profiling in ovarian cancer and ovarian borderline tumors is discussed, focusing on three main areas: distinguishing normal ovarian tissue from ovarian cancers and borderline tumors, identifying different genotypes of ovarian tissue and identifying proteins linked to cancer or tumor development.
  • By these targets, authors focus on the use of novel molecules, developed on the proteomics and genomics researches, as potential protein biomarkers in the management of ovarian cancer or borderline tumor, overlooking on current state of the art and on future perspectives of researches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1922-7 [11747335.001]
  • [Cites] Ann Epidemiol. 2001 Nov;11(8):568-74 [11709277.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6503-15 [11641774.001]
  • [Cites] Tumour Biol. 2001 Sep-Oct;22(5):282-5 [11553857.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27371-5 [11369781.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8018-23 [11416160.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):4965-8 [11326648.001]
  • [Cites] Oncogene. 2009 Mar 5;28(9):1206-17 [19151754.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):475-80 [19150122.001]
  • [Cites] Int J Biochem Cell Biol. 2009 May;41(5):1034-45 [18930836.001]
  • [Cites] Br J Cancer. 2009 Jan 13;100(1):134-44 [19088723.001]
  • [Cites] Acta Obstet Gynecol Scand. 2008;87(12):1353-60 [18951210.001]
  • [Cites] Biochem Pharmacol. 2008 Sep 15;76(6):707-16 [18644348.001]
  • [Cites] Endocrinology. 2008 Aug;149(8):3809-16 [18450971.001]
  • [Cites] FEBS Lett. 2008 Jun 18;582(14):2102-11 [18396168.001]
  • [Cites] Histol Histopathol. 2008 Aug;23(8):935-44 [18498068.001]
  • [Cites] Mol Cancer Res. 2008 May;6(5):695-705 [18505915.001]
  • [Cites] J Proteome Res. 2007 Nov;6(11):4127-34 [17939699.001]
  • [Cites] Micron. 2007;38(8):824-33 [17709250.001]
  • [Cites] Mol Carcinog. 2007 Aug;46(8):725-31 [17610223.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2509-17 [17547437.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):1993-2002 [17620429.001]
  • [Cites] Cancer. 2007 May 1;109(9):1887-96 [17373668.001]
  • [Cites] Ann Oncol. 2007 May;18(5):881-5 [17301071.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jan;26(1):10-5 [17197890.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):924-31 [16842844.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2730-40 [17063503.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70 [17077358.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1511-9 [16944535.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9017-25 [16982743.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1407-18 [16902988.001]
  • [Cites] Clin Obstet Gynecol. 2006 Sep;49(3):433-47 [16885651.001]
  • [Cites] EMBO Rep. 2006 Jun;7(6):599-604 [16741504.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(2):171-6 [16620064.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1707-14 [16551853.001]
  • [Cites] Ann Intern Med. 2006 Mar 21;144(6):397-406 [16549852.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1487-93 [16533772.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Pathol Int. 2006 Feb;56(2):62-70 [16445817.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9338-43 [16361633.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] Am J Obstet Gynecol. 2005 Nov;193(5):1630-9 [16260202.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9415-25 [16230405.001]
  • [Cites] Mol Endocrinol. 2005 Oct;19(10):2564-78 [15928314.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5764-74 [16123809.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):618-23 [16014115.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82 [15890779.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1729-36 [15841084.001]
  • [Cites] Eur J Cancer. 2005 Feb;41(3):461-9 [15691647.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Nat Med. 1999 Aug;5(8):938-42 [10426319.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6249-54 [10339573.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):849-51 [10216504.001]
  • [Cites] Clin Chem. 1999 May;45(5):651-8 [10222351.001]
  • [Cites] Anal Chem. 1997 Dec 1;69(23):4751-60 [9406525.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):922-8 [9269828.001]
  • [Cites] Genomics. 1997 Mar 1;40(2):371-4 [9119409.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6316-24 [2174105.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Sep;84(18):6379-83 [2819873.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5145-50 [15297418.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1153-9 [15138549.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):35-49 [15027884.001]
  • [Cites] Annu Rev Immunol. 2004;22:329-60 [15032581.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):761-8 [14984938.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Mol Cancer Ther. 2003 Oct;2(10):1067-78 [14578472.001]
  • [Cites] J Clin Pathol. 2003 Oct;56(10):764-8 [14514780.001]
  • [Cites] Exp Cell Res. 2003 Aug 15;288(2):382-9 [12915129.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):194s-199s [12743134.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):433-73 [12663865.001]
  • [Cites] Nature. 2002 Nov 7;420(6911):19 [12422186.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):41-7 [11163149.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] Adv Cancer Res. 2000;77:81-137 [10549356.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(2):103-8 [17479670.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(2):83-8 [17479666.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2426-34 [17294443.001]
  • [Cites] J Proteome Res. 2007 Apr;6(4):1440-50 [17315909.001]
  • [Cites] J Proteome Res. 2007 Apr;6(4):1295-305 [17291023.001]
  • [Cites] Am J Obstet Gynecol. 2007 Apr;196(4):348.e1-5 [17403417.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):139-47 [17218951.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1670-9 [17308108.001]
  • [Cites] Trends Biotechnol. 2007 Mar;25(3):111-8 [17257698.001]
  • [Cites] J Proteome Res. 2007 Feb;6(2):772-80 [17269733.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4943-8 [17214367.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4721-8 [17214332.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):332-40 [17154180.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 14;1602(1):47-59 [11960694.001]
  • [Cites] Br J Nutr. 2002 Jan;87 Suppl 1:S23-9 [11895152.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Proteomics. 2002 Jan;2(1):76-84 [11788994.001]
  • (PMID = 19949545.001).
  • [ISSN] 1875-5488
  • [Journal-full-title] Current genomics
  • [ISO-abbreviation] Curr. Genomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2709935
  • [Keywords] NOTNLM ; Ovarian cancer / borderline ovarian tumors / genomics / markers / oncogenes. / proteomics
  •  go-up   go-down


89. Kovalenko TF, Vaniusheva OV, Shilov IA, Sosin DV, Sukhoverkhova AS, Kozlova TV, Bokarev IN, Sorokina AV, Ozolinia LA, Patrushev LI: [Promoters of genes MTHFR from patients with hyperhomocysteinemia and PTEN from patients with malignant and benign endometrial and ovarian tumors]. Bioorg Khim; 2006 Jul-Aug;32(4):414-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Promoters of genes MTHFR from patients with hyperhomocysteinemia and PTEN from patients with malignant and benign endometrial and ovarian tumors].
  • Mutational changes in the promoter regions of MTHFR genes from patients with hyperhomocysteinemia and PTEN genes from patients with endometrial and ovarian tumors were studied.
  • A PCR analysis of the minimal promoter region of the tumor suppressor PTEN in the presence of 2-pyrrolidone in 101 patients from Moscow clinics revealed changes in it in patients with endometrial (56%) or ovarian (29%) cancer, as well as in patients with endometrial hyperplasia and benign ovarian tumors (34.6 and 29%, respectively).
  • As a result of the studies, new molecular markers associated with endometrial and ovarian tumors were revealed and a simple and effective method of detection of these markers was developed.
  • [MeSH-major] 5,10-Methylenetetrahydrofolate Reductase (FADH2) / genetics. Biomarkers, Tumor / genetics. Endometrial Neoplasms / genetics. Hyperhomocysteinemia / genetics. Ovarian Neoplasms / genetics. PTEN Phosphohydrolase / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909866.001).
  • [ISSN] 0132-3423
  • [Journal-full-title] Bioorganicheskaia khimiia
  • [ISO-abbreviation] Bioorg. Khim.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; EC 1.5.1.20 / 5,10-Methylenetetrahydrofolate Reductase (FADH2); EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


90. Mousavi AS, Borna S, Moeinoddini S: Estimation of probability of malignancy using a logistic model combining color Doppler ultrasonography, serum CA125 level in women with a pelvic mass. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:92-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of this study was to develop a scoring system using combination of Doppler characterization of pelvic/ovarian lesions and serum CA125 level.
  • Our purpose was to maximize the preoperative discrimination between benign and malignant entities.
  • The variables that were analyzed by the multivariate logistic regression method are as follows: tumor structure, ascites, presence of septum, the peak systolic velocity (PSV), the resistance index (RI), and serum CA125 level.
  • Of the 101 patients qualified for the study, 48 patients were diagnosed with benign (47.5%) and 53 (52.5%) with malignant tumors.
  • Each criterion used alone provides statistically significant discrimination between benign and malignant tumors.
  • Four criteria could be combined in a malignancy score which is calculated using the product of the serum CA125 level (1 if CA125 > or =40 U/mL and 0 if CA125 <40 U/mL), the result of sonography for presence of septum in tumor (1 if there was septum > or =3 mm, 0 if there was no septum or <3 mm), result of Doppler flow imaging as RI (1 if RI < or =0.5 and 0 if RI >0.5) and the PSV (1 if PSV > or =40 cm/s and 0 if PSV <40 cm/s).
  • This scoring system devised was statistically more effective discriminator between cancer and benign lesions than formal methods.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Pelvic Neoplasms / blood. Pelvic Neoplasms / diagnosis. Ultrasonography, Doppler, Color

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515574.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


91. Fleischer AC, Lyshchik A, Jones HW Jr, Crispens M, Loveless M, Andreotti RF, Williams PK, Fishman DA: Contrast-enhanced transvaginal sonography of benign versus malignant ovarian masses: preliminary findings. J Ultrasound Med; 2008 Jul;27(7):1011-8; quiz 1019-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast-enhanced transvaginal sonography of benign versus malignant ovarian masses: preliminary findings.
  • OBJECTIVE: The aim of this prospective study was to evaluate differences in contrast enhancement and contrast enhancement kinetics in benign versus malignant ovarian masses with pulse inversion harmonic transvaginal sonography.
  • METHODS: Seventeen consecutive patients with 23 morphologically abnormal ovarian masses (solid or cystic with papillary excrescences, focally thickened walls, or irregular solid areas) smaller than 10 cm received a microbubble contrast agent intravenously while undergoing pulse inversion harmonic transvaginal sonography.
  • The following parameters were assessed in all tumors: detectable contrast enhancement, time to peak enhancement (wash-in), peak contrast enhancement, half wash-out time, and area under the enhancement curve.
  • Tumor histologic analysis was used to distinguish benign from malignant ovarian tumors.
  • RESULTS: Fourteen benign masses and 9 malignancies were studied.
  • There was a statistically significant difference in the peak enhancement (mean +/- SD, 23.3 +/- 2.8 versus 12.3 +/- 3.9 dB; P < .01), half wash-out time (139.9 +/- 43.6 versus 46.3 +/- 19.7 seconds; P < .01), and area under the enhancement curve (2012.9 +/- 532.9 versus 523.9 +/- 318 seconds(-1); P < .01) in malignant masses compared with benign disease.
  • CONCLUSIONS: Overall, our data showed a significant difference in the contrast enhancement kinetic parameters between benign and malignant ovarian masses.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / pathology. Contrast Media. Endosonography / methods. Image Enhancement / methods. Ovarian Neoplasms / diagnosis. Ovary / ultrasonography
  • [MeSH-minor] Adult. Aged. Area Under Curve. Diagnosis, Differential. Female. Fluorocarbons. Humans. Image Processing, Computer-Assisted / methods. Kinetics. Microbubbles. Middle Aged. Ovarian Diseases / diagnosis. Prospective Studies. Reproducibility of Results. Ultrasonography, Doppler, Color / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18577664.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA 125227-01
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Definity; 0 / Fluorocarbons
  •  go-up   go-down


92. Fujita T, Hayashi K, Katanoda K, Matsumura Y, Lee JS, Takagi H, Suzuki S, Mizunuma H, Aso T: Prevalence of diseases and statistical power of the Japan Nurses' Health Study. Ind Health; 2007 Oct;45(5):687-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For all diseases except ovarian cancer, the prevalence of a past diagnosis increased markedly with age, and incidence rates could be predicted based on the degree of increase in prevalence between two adjacent 5-yr age groups.
  • The predicted incidence rate for uterine myoma, hypercholesterolemia, and hypertension was > or =3.0 (per 1,000 women, per year), while the rate of thyroid disease, hepatitis, gallstone disease, and benign breast tumor was predicted to be > or =1.0.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057812.001).
  • [ISSN] 0019-8366
  • [Journal-full-title] Industrial health
  • [ISO-abbreviation] Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


93. Pillay OC, Te Fong LF, Crow JC, Benjamin E, Mould T, Atiomo W, Menon PA, Leonard AJ, Hardiman P: The association between polycystic ovaries and endometrial cancer. Hum Reprod; 2006 Apr;21(4):924-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Women with polycystic ovary syndrome (PCOS) are assumed to be at increased risk of endometrial cancer (EC), albeit of a more differentiated type with better prognosis than in normal women.
  • METHODS: The prevalence of polycystic ovaries (PCO), as a marker of PCOS, was investigated in ovarian sections from 128 women with EC and 83 with benign gynaecological conditions.
  • RESULTS: Overall, PCO were similarly prevalent in women with EC (8.6%) and benign controls (8.4%); however, in women aged <50 years, PCO were more prevalent in women with EC (62.5 versus 27.3%, P = 0.033).
  • [MeSH-major] Endometrial Neoplasms / complications. Polycystic Ovary Syndrome / complications
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Cyclin D1 / metabolism. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Middle Aged. Ovary / pathology. Prognosis. Proto-Oncogene Proteins / metabolism. Risk Factors. Tumor Suppressor Protein p53 / metabolism


94. Virk R, Lu D: Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary. Pathol Res Pract; 2010 Jul 15;206(7):489-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary.
  • Sertoli-Leydig cell tumor (SLCT) is a rare tumor involving the ovary.
  • SLCT with benign and borderline mucinous neoplasm has been reported in the literature.
  • Herein, we describe a rare case of intermediately differentiated Sertoli-Leydig cell tumor with mucinous adenocarcinoma as the heterologous element in a 21-year-old woman.
  • She presented with throbbing lower abdominal pain and was found to have a large, complex left ovarian mass on imaging studies.
  • Gross examination of the surgical specimen showed a large, encapsulated, solid-cystic mass completely replacing the ovary.
  • Microscopically, the tumor was composed of intermediately differentiated Sertoli-Leydig cell tumor and well-differentiated mucinous adenocarcinoma.
  • Interestingly, the bulk of the tumor (more than 90%) was composed of mucinous adenocarcinoma, whereas the SLCT component comprised less than 10% of the total tumor.
  • The histopathological features and results of immunostaining were consistent with the diagnosis of the intermediately differentiated SLCT with mucinous adenocarcinoma as the heterologous element.
  • This case was a diagnostic challenge as more than 90% of the tumor was composed of mucinous adenocarcinoma and SLCT constituted only the minor part of the tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009. Published by Elsevier GmbH.
  • (PMID = 19674851.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


95. Lee WA: Mucinous cystadenoma of the pancreas with predominant stroma creating a solid tumor. World J Surg Oncol; 2005 Sep 7;3:59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystadenoma of the pancreas with predominant stroma creating a solid tumor.
  • BACKGROUND: Mucinous cystic neoplasm (MCN) of the pancreas is basically cystic epithelial neoplasm, unilocular or multilocular, occurring almost exclusively in women.
  • The subepithelial stromal component was composed of cytologically bland looking spindle cells, which resembled ovarian stroma.
  • CONCLUSION: This case of mucinous cystadenoma of the pancreas showed very interesting pathology: It was solid rather than cystic, and accompanied by abundant benign transitional epithelia, which was a very unusual and novel finding in the mucinous cystic neoplasm of the pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):86-91 [10658914.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):31-42 [10721805.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):66-80 [10721808.001]
  • [Cites] Verh Dtsch Ges Pathol. 2001;85:219-28 [11894402.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(1):116-9 [12021906.001]
  • [Cites] Pathol Int. 1997 Nov;47(11):806-8 [9413043.001]
  • [Cites] Int J Gynecol Pathol. 1993 Apr;12(2):128-33 [8463036.001]
  • [Cites] Obstet Gynecol. 1979 Nov;54(5):660-3 [503400.001]
  • [Cites] Cancer. 1979 May;43(5):1830-9 [445369.001]
  • [Cites] Pathologica. 1989 Jul-Aug;81(1074):381-401 [2696922.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):148-52 [15354741.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Apr;19(4):467-70 [15012791.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):1-16 [9888699.001]
  • (PMID = 16146567.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1236970
  •  go-up   go-down


96. Van Holsbeke C, Van Belle V, Leone FP, Guerriero S, Paladini D, Melis GB, Greggi S, Fischerova D, De Jonge E, Neven P, Bourne T, Valentin L, Van Huffel S, Timmerman D: Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology. Ultrasound Obstet Gynecol; 2010 Jul;36(1):81-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology.
  • OBJECTIVE: To determine the sensitivity and specificity of the 'ovarian crescent sign' (OCS)-a rim of normal ovarian tissue seen adjacent to an ipsilateral adnexal mass-as a sonographic feature to discriminate between benign and malignant adnexal masses.
  • METHODS: The patients included were a subgroup of patients participating in the International Ovarian Tumor Analysis (IOTA) Phase 2 study, which is an international multicenter study.
  • The gold standard was the histological diagnosis of the adnexal mass.
  • The ability of the OCS to discriminate between borderline or invasively malignant vs. benign adnexal masses, as well as between invasively malignant vs. other (benign and borderline) tumors, was determined and compared with the performance of subjective evaluation of ultrasound findings by the ultrasound examiner.
  • RESULTS: The OCS was evaluated in 1377 adnexal masses from 12 centers, 938 (68%) masses being benign, 86 (6%) borderline, 305 (22%) primary invasive and 48 (3%) metastases.
  • The OCS was present in 398 (42%) of 938 benign masses, in 14 (16%) of 86 borderline tumors, in 18 (6%) of 305 primary invasive tumors (one malignant struma ovarii, one uterine clear cell adenocarcinoma and 16 epithelial carcinomas, i.e. four Stage I and 12 Stage II-IV) and in two (4%) of 48 ovarian metastases.
  • For discrimination between invasive vs. benign or borderline tumors, the sensitivity for absent OCS was 94%, the specificity was 40%, the LR+ was 1.58 and the LR- was 0.14.
  • However it is a poor discriminator between benign and malignant adnexal masses.
  • [MeSH-major] Ovarian Neoplasms / ultrasonography. Ovary / ultrasonography
  • [MeSH-minor] Adnexal Diseases / ultrasonography. Diagnosis, Differential. Female. Humans. Neoplasm Staging. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 20217895.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


97. Okuma E, Ohishi Y, Oda Y, Aishima S, Kurihara S, Nishimura I, Yasunaga M, Kobayashi H, Wake N, Tsuneyoshi M: Cytoplasmic and stromal expression of laminin γ 2 chain correlates with infiltrative invasion in ovarian mucinous neoplasms of gastro-intestinal type. Oncol Rep; 2010 Dec;24(6):1569-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic and stromal expression of laminin γ 2 chain correlates with infiltrative invasion in ovarian mucinous neoplasms of gastro-intestinal type.
  • Ovarian mucinous neoplasms of gastro-intestinal type (GI-type) are known to be a heterogeneous tumor composed of benign, borderline and non-invasive and invasive malignant lesions.
  • The presence of infiltrative invasion is also known to be an important prognostic factor of this neoplasm.
  • Laminin γ 2 chain, known to stimulate tumor cell invasion and migration, has not been sufficiently investigated in ovarian mucinous neoplasms.
  • The purpose of this study was thus to clarify the role of laminin γ 2 in ovarian mucinous neoplasms of GI-type.
  • We selected each morphological phase of tumor development from 61 cases of mucinous neoplasms of the GI-type: 55 adenoma lesions, 60 borderline lesions, 20 microinvasive lesions, 17 intraepithelial carcinoma lesions, 38 expansile invasive carcinoma lesions, 19 infiltrative invasive carcinoma lesions and 5 mural nodules lesions; and evaluated the localization of laminin γ 2 in the lesions using immunohistochemical method.
  • The infiltrative invasion of GI-type ovarian mucinous neoplasms may be promoted by cytoplasmic and/or stromal expression of laminin γ 2 chain.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Gastrointestinal Neoplasms / pathology. Laminin / metabolism. Neoplasm Staging / methods. Ovarian Neoplasms / secondary
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cohort Studies. Cytoplasm / metabolism. Disease Progression. Female. Humans. Models, Biological. Neoplasm Invasiveness. Prognosis. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042753.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / LAMC2 protein, human; 0 / Laminin
  •  go-up   go-down


98. Lanowska M, Favero G, Schneider A, Köhler C: Laparoscopy for differential diagnosis of a pelvic mass in a patient with Mayer-Rokitanski-Küster-Hauser (MRKH) syndrome. Fertil Steril; 2009 Mar;91(3):931.e17-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy for differential diagnosis of a pelvic mass in a patient with Mayer-Rokitanski-Küster-Hauser (MRKH) syndrome.
  • OBJECTIVE: To report a rare case of a myoma simulating a pelvic tumor in a patient with Mayer-Rokitanski-Küster-Hauser (MRKH) syndrome.
  • The rudimentary uterus may develop fibroids, and this event can lead to problems in differential diagnosis, especially if no vaginal reconstruction has been carried out.
  • PATIENT(S): A 39-year-old patient with MRKH syndrome presented with a solid pelvic mass 9 cm in diameter on ultrasound and magnetic resonance imaging that could not be differentiated between fibroid and ovarian tumor.
  • RESULT(S): Histology confirmed a benign leiomyoma.
  • CONCLUSION(S): In patients with MRKH syndrome, laparoscopy allows analysis of the origin of a solid pelvic tumor and its removal.
  • [MeSH-major] Abnormalities, Multiple / pathology. Laparoscopy. Leiomyoma / pathology. Ovarian Neoplasms / diagnosis. Uterine Neoplasms / pathology. Uterus / abnormalities. Vagina / abnormalities
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Gynecologic Surgical Procedures. Humans. Magnetic Resonance Imaging. Syndrome. Treatment Outcome


99. Timms JF, Cramer R, Camuzeaux S, Tiss A, Smith C, Burford B, Nouretdinov I, Devetyarov D, Gentry-Maharaj A, Ford J, Luo Z, Gammerman A, Menon U, Jacobs I: Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer. Clin Chem; 2010 Feb;56(2):262-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.
  • Previous mass spectrometry (MS) studies have suggested that groups of related peptides discriminatory for different cancer types are generated ex vivo from abundant serum proteins by tumor-specific exopeptidases.
  • We tested 2 complementary serum profiling strategies to see if similar peptides could be found that discriminate ovarian cancer from benign cases and healthy controls.
  • In cross-validation, models from training data gave diagnostic accuracies up to 87% for discriminating malignant ovarian cancer from healthy controls and up to 81% for discriminating malignant from benign samples.
  • Diagnostic accuracies up to 71% (malignant vs healthy) and up to 65% (malignant vs benign) were obtained when the models were validated on the blinded test set.
  • CONCLUSIONS: For ovarian cancer, altered MALDI-TOF MS peptide profiles alone cannot be used for accurate diagnoses.
  • [MeSH-major] Biomarkers, Tumor / blood. Blood Proteins / metabolism. Exopeptidases / metabolism. Ovarian Neoplasms / blood
  • [MeSH-minor] Aged. Case-Control Studies. Diagnosis, Differential. Female. Humans. Middle Aged. Reproducibility of Results. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20093557.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0801228; United Kingdom / Medical Research Council / / G9901012; United Kingdom / Medical Research Council / / G0301107; United Kingdom / Medical Research Council / / G0401619
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; EC 3.4.- / Exopeptidases
  •  go-up   go-down


100. Hoffman JG, Strickland JL, Yin J: Virilizing ovarian dermoid cyst with leydig cells. J Pediatr Adolesc Gynecol; 2009 Jun;22(3):e39-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virilizing ovarian dermoid cyst with leydig cells.
  • Overall, ovarian tumors causing virilization are exceedingly rare and mostly occur in post-menopausal women.
  • In fact, there are no reported cases of virilization from a testosterone-producing ovarian dermoid in the adolescent female age group.
  • The most frequent germ cell tumor derived from the ovaries is the benign cystic teratoma (dermoid) which accounts for 25% of all ovarian neoplasms.
  • Usually the tumors are asymptomatic, but they occasionally can cause severe pain if there is torsion or if sebaceous material perforates the cyst wall, leading to reactive peritonitis.
  • CASE: A 12-year-old female was found to have a large 3 5 x 19 x 12 cm ovarian mature cystic teratoma arising from her right ovary.
  • CONCLUSION: Benign cystic teratomas can produce active hormones, albeit rarely.
  • This is a finding important to consider when ovarian cystectomy is performed for removal of a benign cystic teratoma.
  • [MeSH-major] Dermoid Cyst / pathology. Dermoid Cyst / secretion. Leydig Cells / secretion. Ovarian Neoplasms / pathology. Ovarian Neoplasms / secretion. Virilism / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19539195.001).
  • [ISSN] 1873-4332
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3XMK78S47O / Testosterone
  •  go-up   go-down






Advertisement